e424b5
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of
|
|
|
|
Amount
|
|
|
Aggregate Price
|
|
|
Aggregate
|
|
|
Registration
|
|
|
|
Registered
|
|
|
Per Unit
|
|
|
Offering Price
|
|
|
Fee(1)
|
4.500% Senior Notes due 2021
|
|
|
$300,000,000
|
|
|
99.497%
|
|
|
$298,491,000
|
|
|
$34,654.81
|
5.875% Senior Notes due 2041
|
|
|
$300,000,000
|
|
|
99.356%
|
|
|
$298,068,000
|
|
|
$34,605.69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Calculated in accordance with Rule 457(r) under the
Securities Act of 1933, as amended (the Securities
Act). Payment of the registration fee at the time of
filing of the registrants registration statement on
Form S-3
filed with the Securities and Exchange Commission on
August 10, 2009 (File
No. 333-161227),
was deferred pursuant to Rules 456(b) and 457(r) or the
Securities Act, and is paid herewith. This Calculation of
Registration Fee table shall be deemed to update the
Calculation of Registration Fee table in such
registration statement.
|
Filed Pursuant to Rule 424B5
Registration No. 333-161227
Prospectus Supplement
(To Prospectus dated August 10, 2009)
$600,000,000
CIGNA Corporation
4.500% Senior Notes due
2021
5.875% Senior Notes due
2041
We are offering $300,000,000 of our 4.500% senior notes due
2021 (the
10-Year
Notes) and $300,000,000 of our 5.875% senior notes
due 2041 (the
30-Year
Notes and, together with the
10-Year
Notes, the Notes).
The 10-Year
Notes will bear interest at the rate of 4.500% per year.
Interest on the
10-Year
Notes is payable on March 15 and September 15 of each year,
beginning September 15, 2011. The
10-Year
Notes will mature on March 15, 2021.
The 30-Year
Notes will bear interest at the rate of 5.875% per year.
Interest on the
30-Year
Notes is payable on March 15 and September 15 of each year,
beginning September 15, 2011. The
30-Year
Notes will mature on March 15, 2041.
We may redeem the Notes, at any time in whole or from time to
time in part, as described under the caption Description
of the Notes Optional Redemption in this
prospectus supplement. If a change of control triggering event
as described herein occurs with respect to the
10-Year
Notes or the
30-Year
Notes, we will be required to offer to repurchase the
10-Year
Notes or the
30-Year
Notes, as applicable, at the price described in this prospectus
supplement.
The Notes will be senior unsecured obligations of our company
and will rank equally with all of our other existing and future
senior unsecured indebtedness.
Investing in the Notes involves certain risks. See
Special Note Regarding Forward-Looking Statements and Risk
Factors on page ii of this prospectus supplement and
Risk Factors beginning on page 33 in our Annual
Report on
Form 10-K
for the year ended December 31, 2010, which is incorporated
by reference herein.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per 10-Year
|
|
10-Year Note
|
|
Per 30-Year
|
|
30-Year Note
|
|
|
Note
|
|
Total
|
|
Note
|
|
Total
|
|
Public offering price (1)
|
|
|
99.497
|
%
|
|
$
|
298,491,000
|
|
|
|
99.356
|
%
|
|
$
|
298,068,000
|
|
Underwriting discount
|
|
|
0.650
|
%
|
|
$
|
1,950,000
|
|
|
|
0.875
|
%
|
|
$
|
2,625,000
|
|
Proceeds, before expenses to CIGNA Corporation (1)
|
|
|
98.847
|
%
|
|
$
|
296,541,000
|
|
|
|
98.481
|
%
|
|
$
|
295,443,000
|
|
|
|
|
(1) |
|
Plus accrued interest, if any, from March 7, 2011, to the
date of delivery. |
Neither the Securities and Exchange Commission (the
SEC) nor any state securities commission has
approved or disapproved of these securities or determined if
this prospectus supplement or the accompanying prospectus is
truthful or complete. Any representation to the contrary is a
criminal offense.
The underwriters expect to deliver the Notes in book-entry form
only through the facilities of The Depository Trust Company
for the accounts of its participants, including Clearstream
Banking, S.A. and Euroclear Bank S.A./N.V., as
operator of the Euroclear System, against payment in New York,
New York on or about March 7, 2011.
Joint Book-Running Managers
|
|
|
BofA
Merrill Lynch |
Morgan Stanley |
Wells Fargo Securities |
March 2, 2011
Neither we nor the underwriters have authorized any other person
to provide you with different or additional information other
than that contained in or incorporated by reference in this
prospectus supplement and the accompanying prospectus and in any
free writing prospectus filed by the Company with the SEC. We
and the underwriters take no responsibility for, and can provide
no assurance as to the reliability of, any other information
that others may provide. This prospectus supplement and the
accompanying prospectus may only be used where it is legal to
sell these securities. The information in this prospectus
supplement and the accompanying prospectus may only be accurate
as of the date of this prospectus supplement, the accompanying
prospectus or the information incorporated by reference herein
or therein, and the information in any free writing prospectus
may only be accurate as of the date of such free writing
prospectus. Our business, financial condition, results of
operations
and/or
prospects may have changed since those dates.
TABLE OF
CONTENTS
Prospectus Supplement
|
|
|
|
|
|
|
Page
|
|
|
|
|
ii
|
|
|
|
|
iv
|
|
|
|
|
S-1
|
|
|
|
|
S-4
|
|
|
|
|
S-5
|
|
|
|
|
S-5
|
|
|
|
|
S-6
|
|
|
|
|
S-16
|
|
|
|
|
S-19
|
|
|
|
|
S-23
|
|
|
|
|
S-23
|
|
|
|
|
S-24
|
|
Prospectus
Page
|
|
|
|
|
|
|
Page
|
|
About This Prospectus
|
|
|
2
|
|
Special Note on Forward-Looking Statements and Risk Factors
|
|
|
3
|
|
Where You Can Find More Information
|
|
|
5
|
|
Cigna Corporation
|
|
|
6
|
|
Use of Proceeds
|
|
|
6
|
|
Description of Debt Securities
|
|
|
6
|
|
Form of Debt Securities
|
|
|
12
|
|
Description of Capital Stock
|
|
|
14
|
|
Plan of Distribution
|
|
|
15
|
|
Validity of Securities
|
|
|
18
|
|
Experts
|
|
|
18
|
|
ERISA Matters
|
|
|
18
|
|
Unless otherwise mentioned or unless the context requires
otherwise (including when describing the terms of the Notes),
when used in this prospectus supplement and accompanying
prospectus, the terms CIGNA, we,
our and us refer to CIGNA Corporation
and its consolidated subsidiaries, and the term the
Company refers to CIGNA Corporation, not including
its consolidated subsidiaries. The underwriters
refers to the financial institutions named in the
Underwriting section of this prospectus supplement.
i
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK
FACTORS
We have made forward-looking statements in this prospectus
supplement, the accompanying prospectus and the documents
incorporated by reference herein and therein. Forward-looking
statements may contain information about financial prospects,
economic conditions, trends and other uncertainties. These
forward-looking statements are based on managements
beliefs and assumptions and on information available to
management at the time the statements are or were made.
Forward-looking statements include but are not limited to the
information concerning possible or assumed future business
strategies, financing plans, competitive position, potential
growth opportunities, potential operating performance
improvements, trends, and, in particular, CIGNAs
productivity initiatives, litigation and other legal matters,
operational improvement in the health care operations, and the
outlook for CIGNAs full year 2011 results. Forward-looking
statements include all statements that are not historical facts
and can be identified by the use of forward-looking terminology
such as the words believe, expect,
plan, intend, anticipate,
estimate, predict,
potential, may, should,
outlook, guidance, forecast,
expectations or similar expressions.
By their nature, forward-looking statements: (i) speak only
as of the date they are made, (ii) are not guarantees of
future performance or results and (iii) are subject to
risks, uncertainties and assumptions that are difficult to
predict or quantify. Therefore, actual results could differ
materially and adversely from those forward-looking statements
as a result of a variety of factors. Some factors that could
cause actual results to differ materially from the
forward-looking statements include:
|
|
|
|
1.
|
increased medical costs that are higher than anticipated in
establishing premium rates in CIGNAs Health Care
operations, including increased use and costs of medical
services;
|
|
|
2.
|
increased medical, administrative, technology or other costs
resulting from new legislative and regulatory requirements
imposed on CIGNAs businesses;
|
|
|
3.
|
challenges and risks associated with implementing operational
improvement initiatives and strategic actions in the ongoing
operations of the businesses, including those related to:
(i) growth in targeted geographies, product lines, buying
segments and distribution channels, (ii) offering products
that meet emerging market needs, (iii) strengthening
underwriting and pricing effectiveness, (iv) strengthening
medical cost and medical membership results, (v) delivering
quality member and provider service using effective technology
solutions, (vi) lowering administrative costs and
(vii) transitioning to an integrated operating company
model, including operating efficiencies related to the
transition;
|
|
|
4.
|
risks associated with pending and potential state and federal
class action lawsuits, disputes regarding reinsurance
arrangements, other litigation and regulatory actions
challenging CIGNAs businesses, including disputes related
to payments to health care professionals, government
investigations and proceedings, and tax audits and related
litigation;
|
|
|
5.
|
heightened competition, particularly price competition, which
could reduce product margins and constrain growth in
CIGNAs businesses, primarily the Health Care business;
|
|
|
6.
|
risks associated with CIGNAs mail order pharmacy business
which, among other things, includes any potential operational
deficiencies or service issues as well as loss or suspension of
state pharmacy licenses;
|
|
|
7.
|
significant changes in interest rates or sustained deterioration
in the commercial real estate markets;
|
|
|
8.
|
downgrades in the financial strength ratings of CIGNAs
insurance subsidiaries, which could, among other things,
adversely affect new sales, retention of current business as
well as a downgrade in financial strength ratings of reinsurers
which could result in increased statutory reserve or capital
requirements;
|
|
|
9.
|
limitations on the ability of CIGNAs insurance
subsidiaries to dividend capital to the parent company as a
result of downgrades in the subsidiaries financial
strength ratings, changes in statutory reserve or capital
requirements or other financial constraints;
|
ii
|
|
|
|
10.
|
inability of the program adopted by CIGNA to substantially
reduce equity market risks for reinsurance contracts that
guarantee minimum death benefits under certain variable
annuities (including possible market difficulties in entering
into appropriate futures contracts and in matching such
contracts to the underlying equity risk);
|
|
|
11.
|
adjustments to the reserve assumptions (including lapse, partial
surrender, mortality, interest rates and volatility) used in
estimating CIGNAs liabilities for reinsurance contracts
covering guaranteed minimum death benefits under certain
variable annuities;
|
|
|
12.
|
adjustments to the assumptions (including annuity election rates
and amounts collectible from reinsurers) used in estimating
CIGNAs assets and liabilities for reinsurance contracts
covering guaranteed minimum income benefits under certain
variable annuities;
|
|
|
13.
|
significant stock market declines, which could, among other
things, result in increased expenses for guaranteed minimum
income benefit contracts, guaranteed minimum death benefit
contracts and CIGNAs pension plans in future periods as
well as the recognition of additional pension obligations;
|
|
|
14.
|
significant deterioration in economic conditions and significant
market volatility, which could have an adverse effect on
CIGNAs operations, investments, liquidity and access to
capital markets;
|
|
|
15.
|
significant deterioration in economic conditions and significant
market volatility, which could have an adverse effect on the
businesses of CIGNAs customers (including the amount and
type of health care services provided to their workforce, loss
in workforce and our customers ability to pay receivables)
and CIGNAs vendors (including their ability to provide
services);
|
|
|
16.
|
adverse changes in state, federal and international laws and
regulations, including health care reform legislation and
regulation which could, among other items, affect the way CIGNA
does business, increase cost, limit the ability to effectively
estimate, price for and manage medical costs, and affect
CIGNAs health care products, services, market segments,
technology and processes;
|
|
|
17.
|
amendments to income tax laws, which could affect the taxation
of employer provided benefits, the taxation of certain insurance
products such as corporate-owned life insurance, or the
financial decisions of individuals whose variable annuities are
covered under reinsurance contracts issued by CIGNA;
|
|
|
18.
|
potential public health epidemics, pandemics and bio-terrorist
activity, which could, among other things, cause CIGNAs
covered medical and disability expenses, pharmacy costs and
mortality experience to rise significantly, and cause
operational disruption, depending on the severity of the event
and number of individuals affected;
|
|
|
19.
|
risks associated with security or interruption of information
systems, which could, among other things, cause operational
disruption;
|
|
|
20.
|
challenges and risks associated with the successful management
of CIGNAs outsourcing projects or key vendors, including
the agreement with IBM for provision of technology
infrastructure and related services;
|
|
|
21.
|
the ability to successfully complete the integration of acquired
businesses; and
|
|
|
22.
|
the political, legal, operational, regulatory and other
challenges associated with expanding our business globally.
|
This list of important factors is not intended to be exhaustive.
Other sections of our most recent Annual Report on
Form 10-K
for the year ended December 31, 2010, including the
Risk Factors section and other documents filed with
the SEC include both expanded discussion of these factors and
additional risk factors and uncertainties that could preclude
CIGNA from realizing the forward-looking statements. CIGNA does
not assume any obligation to update any forward-looking
statements, whether as a result of new information, future
events or otherwise, except as required by law.
iii
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements
and other information with the SEC under the Securities Exchange
Act of 1934, as amended (the Exchange Act). You may
read and copy all or any portion of this information at the
SECs principal office in Washington, D.C., and copies
of all or any part thereof may be obtained from the Public
Reference Section of the SEC, 100 F Street, N.E.,
Washington, D.C. 20549 after payment of fees prescribed by
the SEC. Please call the SEC at
1-800-SEC-0330
for further information about the public reference room.
The SEC also maintains a website that contains reports, proxy
statements and other information about issuers, like CIGNA, who
file electronically with the SEC. The address of that site is
www.sec.gov.
Our website address is www.cigna.com. This reference to our
website is intended to be an inactive textual reference only.
Our website and the information contained therein or connected
thereto are not incorporated by reference into this prospectus
supplement or the accompanying prospectus.
This prospectus supplement is part of the registration statement
and does not contain all of the information included in the
registration statement. Whenever a reference is made in this
prospectus supplement to any contract or other document of
CIGNA, the reference may not be complete and you should refer to
the exhibits that are a part of the registration statement for a
copy of the contract or document.
The SEC allows us to incorporate by reference
information into this prospectus supplement and the accompanying
prospectus, which means that we can disclose important
information to you by referring you to another document filed
separately with the SEC. The information incorporated by
reference is deemed to be part of this prospectus supplement and
the accompanying prospectus, except for any information that is
superseded by subsequent incorporated documents or by
information that is contained directly in this prospectus
supplement. This prospectus supplement and the accompanying
prospectus incorporates by reference the documents set forth
below that CIGNA has previously filed with the SEC and that are
not delivered with this prospectus supplement. These documents
contain important information about CIGNA and its financial
condition.
|
|
|
CIGNA SEC Filings (File No. 1-08323)
|
|
Filing Dates
|
|
Annual Report on
Form 10-
K
|
|
For the fiscal year ended December 31, 2010, filed on February
25, 2011 (as amended by the Form 10-K/A filed on February 28,
2011).
|
All documents filed by us pursuant to Section 13(a), 13(c),
14 or 15(d) of the Exchange Act (excluding any information
furnished under Item 2.02 or 7.01 in any Current Report on
Form 8-K
or related exhibits furnished pursuant to Item 9.01 of such
form) between the date of this prospectus supplement and the
termination of the offering of the Notes shall also be deemed to
be incorporated herein by reference. Any statement contained in
any document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded
for purposes of this prospectus supplement and the accompanying
prospectus to the extent that a statement contained in this
prospectus supplement or in any other subsequently filed
document which also is or is deemed to be incorporated by
reference in this prospectus supplement and the accompanying
prospectus modifies or supersedes such statement. Any statement
so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this prospectus
supplement and the accompanying prospectus.
To obtain a copy of these filings at no cost, you may write or
telephone us at the following address:
CIGNA
Corporation
Two Liberty Place, 1601 Chestnut Street
Philadelphia, PA 19192
Attention: Investor Relations
(215) 761-1000
Exhibits to the filings will not be sent, however, unless those
exhibits have specifically been incorporated by reference into
such document.
iv
PROSPECTUS
SUPPLEMENT SUMMARY
This summary highlights selected information about CIGNA
Corporation and this offering. It does not contain all of the
information that may be important to you in deciding whether to
purchase the Notes. We encourage you to read the entire
prospectus supplement, the accompanying prospectus and the
documents that we have filed with the SEC that are incorporated
by reference prior to deciding whether to purchase the Notes.
CIGNA
The Company is a global health service organization with
subsidiaries that are major providers of medical, dental,
disability, life and accident insurance and related products and
services. In the U.S., the majority of these products and
services are offered through employers and other groups (e.g.
unions and associations) and in selected international markets,
CIGNA offers supplemental health, life and accident insurance
products, expatriate benefits and international health care
coverage and services to businesses, governmental and
non-governmental organizations and individuals. In addition to
its ongoing operations described above, CIGNA also has certain
run-off operations, including a Run-off Reinsurance segment.
CIGNA Corporation had consolidated shareholders equity of
$6.6 billion and assets of $45.7 billion as of
December 31, 2010, and revenues of $21.3 billion for
the year then ended. CIGNA Corporation was incorporated in the
State of Delaware in 1981.
CIGNA Corporation is a holding company and is not an insurance
company. Its subsidiaries conduct various businesses, which are
described in our most recent Annual Report on
Form 10-K.
CIGNA Corporations principal executive offices are located
at Two Liberty Place, 1601 Chestnut Street, Philadelphia, PA
19192. Our telephone number is
(215) 761-1000.
For additional information concerning CIGNA, please see our most
recent Annual Report on
Form 10-K
and our other filings with the SEC. See Where You Can Find
More Information.
S-1
The
Offering
The terms of the Notes are summarized below solely for your
convenience. This summary is not a complete description of the
Notes. You should read the full text and more specific details
contained elsewhere in this prospectus supplement and the
accompanying prospectus. For a more detailed description of the
Notes, see the discussion under the caption Description of
the Notes beginning on
page S-6
of this prospectus supplement.
|
|
|
Issuer |
|
CIGNA Corporation |
|
Securities Offered |
|
$300,000,000 aggregate principal amount of 4.500% senior
notes due 2021 and $300,000,000 aggregate principal amount of
5.875% senior notes due 2041. |
|
Maturity |
|
The 10-Year
Notes will mature on March 15, 2021, and the
30-Year
Notes will mature on March 15, 2041. |
|
Interest Payment Dates |
|
Interest on the
10-Year
Notes will accrue from March 7, 2011 and will be payable on
March 15 and September 15 of each year, beginning
September 15, 2011. Interest on the
30-Year
Notes will accrue from March 7, 2011 and will be payable on
March 15 and September 15 of each year, beginning
September 15, 2011. |
|
Optional Redemption |
|
Before the date that is three months prior to the maturity date
for the
10-Year
Notes or before the date that is six months prior to the
maturity date for the
30-Year
Notes, we may redeem the
10-Year
Notes or the
30-Year
Notes, respectively, at any time in whole or from time to time
in part, at the redemption price described in this prospectus
supplement. |
|
|
|
If the
10-Year
Notes are redeemed on or after the date that is three months
prior to the maturity date for the
10-Year
Notes or if the
30-Year
Notes are redeemed on or after the date that is six months prior
to the maturity date for the
30-Year
Notes, the
10-Year
Notes or the
30-Year
Notes, respectively, will be redeemable, in whole at any time or
in part from time to time, at our option at par plus accrued
interest thereon to but excluding the redemption date. |
|
Ranking |
|
The Notes will be our senior unsecured and unsubordinated
obligations and will rank equally with all of our existing and
future senior unsecured and unsubordinated indebtedness and
senior to all of our subordinated indebtedness. See
Description of the Notes. |
|
Use of Proceeds |
|
We intend to use the net proceeds from this offering for general
corporate purposes, including the repayment of our
$226 million outstanding 6.375% notes due October
2011. We may invest funds that we do not immediately require in
short-term marketable securities. See Use of
Proceeds. |
|
Change of Control Redemption at the Option of the
Holders
|
|
A Change of Control Triggering Event will be deemed to occur if
both a Change of Control and a Below Investment Grade Rating
Event (each as defined herein under Description of the
Notes Change of Control Offer) occur with
respect to the
10-Year
Notes or the
30-Year
Notes, in which case, unless we have exercised our right to
redeem the
10-Year
Notes or the
30-Year
Notes, as applicable, as described under Description of
the Notes |
S-2
|
|
|
|
|
Optional Redemption, we will be required to make an offer
to purchase all of the
10-Year
Notes or the
30-Year
Notes, as applicable, at a price equal to 101% of the principal
amount of the
10-Year
Notes or the
30-Year
Notes, as applicable, plus any accrued and unpaid interest to
the date of repurchase. See Description of the
Notes Change of Control Offer. |
|
Covenants |
|
The Senior Indenture for the Notes contains limitations on liens
on common stock of our Designated Subsidiaries (as defined in
the Senior Indenture) and limits our ability to consolidate with
or merge with or into any other person (other than in a merger
or consolidation in which we are the surviving person) or sell
our property or assets as, or substantially as, an entirety to
any person. These covenants are subject to important
qualifications and limitations. See Description of Debt
Securities Limitations on Liens on Common Stock of
Designated Subsidiaries and
Consolidation, Merger and Sale of Assets
in the accompanying prospectus. |
|
Minimum Denominations |
|
The Notes will be issued and may be transferred only in minimum
denominations of $2,000 and multiples of $1,000 in excess
thereof. |
|
Risk Factors |
|
For a discussion of factors you should carefully consider before
deciding to purchase the Notes, see Special Note Regarding
Forward-Looking Statements and Risk Factors on page ii of
this prospectus supplement and Risk Factors
beginning on page 33 in our Annual Report on
Form 10-K
for the year ended December 31, 2010. |
S-3
SELECTED
FINANCIAL INFORMATION
The following table sets forth our selected consolidated
financial data for the five years ended December 31, 2010,
2009, 2008, 2007 and 2006.
The following information should be read in conjunction with
Managements Discussion and Analysis of Financial
Condition and Results of Operations and our consolidated
financial statements and related notes included in our Annual
Report on
Form 10-K
for the year ended December 31, 2010, filed with the SEC
and incorporated by reference in this prospectus supplement and
the accompanying prospectus. See Where You Can Find More
Information in this prospectus supplement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(in millions)
|
|
|
Income Statement Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums and fees and other revenues
|
|
$
|
18,653
|
|
|
$
|
16,161
|
|
|
$
|
17,004
|
|
|
$
|
15,376
|
|
|
$
|
13,987
|
|
Net investment income
|
|
|
1,105
|
|
|
|
1,014
|
|
|
|
1,063
|
|
|
|
1,114
|
|
|
|
1,195
|
|
Mail order pharmacy revenues
|
|
|
1,420
|
|
|
|
1,282
|
|
|
|
1,204
|
|
|
|
1,118
|
|
|
|
1,145
|
|
Realized investment gains (losses)
|
|
|
75
|
|
|
|
(43
|
)
|
|
|
(170
|
)
|
|
|
16
|
|
|
|
219
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
21,253
|
|
|
|
18,414
|
|
|
|
19,101
|
|
|
|
17,624
|
|
|
|
16,546
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health Care medical claims expense
|
|
|
8,570
|
|
|
|
6,927
|
|
|
|
7,252
|
|
|
|
6,798
|
|
|
|
6,111
|
|
Other benefit expenses
|
|
|
3,663
|
|
|
|
3,407
|
|
|
|
4,285
|
|
|
|
3,401
|
|
|
|
3,153
|
|
Mail order pharmacy cost of goods sold
|
|
|
1,169
|
|
|
|
1,036
|
|
|
|
961
|
|
|
|
904
|
|
|
|
922
|
|
Other operating expenses (including GMIB fair value gain (loss))
|
|
|
5,981
|
|
|
|
5,146
|
|
|
|
6,221
|
|
|
|
4,887
|
|
|
|
4,629
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total benefits and expenses
|
|
|
19,383
|
|
|
|
16,516
|
|
|
|
18,719
|
|
|
|
15,990
|
|
|
|
14,815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes
|
|
|
1,870
|
|
|
|
1,898
|
|
|
|
382
|
|
|
|
1,634
|
|
|
|
1,731
|
|
Income taxes
|
|
|
521
|
|
|
|
594
|
|
|
|
92
|
|
|
|
511
|
|
|
|
572
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
1,349
|
|
|
|
1,304
|
|
|
|
290
|
|
|
|
1,123
|
|
|
|
1,159
|
|
Income (loss) from discontinued operations, net of taxes
|
|
|
|
|
|
|
1
|
|
|
|
4
|
|
|
|
(5
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
1,349
|
|
|
|
1,305
|
|
|
|
294
|
|
|
|
1,118
|
|
|
|
1,155
|
|
Less: net income attributable to noncontrolling interest
|
|
|
4
|
|
|
|
3
|
|
|
|
2
|
|
|
|
3
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders net income
|
|
$
|
1,345
|
|
|
$
|
1,302
|
|
|
$
|
292
|
|
|
$
|
1,115
|
|
|
$
|
1,155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet Data (At Period End):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
45,682
|
|
|
$
|
43,013
|
|
|
$
|
41,406
|
|
|
$
|
40,065
|
|
|
$
|
42,399
|
|
Debt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term
|
|
$
|
552
|
|
|
$
|
104
|
|
|
$
|
301
|
|
|
$
|
3
|
|
|
$
|
382
|
|
Long-term
|
|
$
|
2,288
|
|
|
$
|
2,436
|
|
|
$
|
2,090
|
|
|
$
|
1,790
|
|
|
$
|
1,294
|
|
Shareholders equity
|
|
$
|
6,645
|
|
|
$
|
5,417
|
|
|
$
|
3,592
|
|
|
$
|
4,748
|
|
|
$
|
4,330
|
|
S-4
USE OF
PROCEEDS
Our net proceeds from this offering are estimated to be
approximately $591 million after deducting underwriting
discounts and our estimated offering expenses. We intend to use
the net proceeds from this offering for general corporate
purposes, including the repayment of our $226 million
outstanding 6.375% notes due October 2011. We may invest
funds that we do not immediately require in short-term
marketable securities.
CAPITALIZATION
The following table shows our capitalization on a consolidated
basis as of December 31, 2010, and as adjusted for the sale
of $300,000,000 aggregate principal amount of
10-Year
Notes and $300,000,000 aggregate principal amount of
30-Year
Notes offered by this prospectus supplement. You should read
this table in conjunction with our consolidated financial
statements and the related notes as of and for the periods ended
December 31, 2010, which are incorporated by reference in
this prospectus supplement and the accompanying prospectus.
|
|
|
|
|
|
|
|
|
|
|
At December 31,
|
|
|
|
2010
|
|
|
|
Actual
|
|
|
As Adjusted
|
|
|
|
(in millions)
|
|
|
Long-term debt
|
|
$
|
2,288
|
|
|
$
|
2,888
|
(1)
|
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Common stock ($0.25 par value)
|
|
|
88
|
|
|
|
88
|
|
Additional paid-in capital
|
|
|
2,534
|
|
|
|
2,534
|
|
Net unrealized appreciation, fixed maturities
|
|
|
529
|
|
|
|
529
|
|
Net unrealized appreciation, equity securities
|
|
|
3
|
|
|
|
3
|
|
Net unrealized depreciation, derivatives
|
|
|
(24
|
)
|
|
|
(24
|
)
|
Net translation of foreign currencies
|
|
|
25
|
|
|
|
25
|
|
Postretirement benefits liability adjustment
|
|
|
(1,147
|
)
|
|
|
(1,147
|
)
|
Retained earnings
|
|
|
9,879
|
|
|
|
9,879
|
|
Treasury stock, at cost
|
|
|
(5,242
|
)
|
|
|
(5,242
|
)
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
6,645
|
|
|
|
6,645
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
8,933
|
|
|
$
|
9,533
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Does not give effect to repayment of our $226 million
outstanding 6.375% notes due October 2011. |
S-5
DESCRIPTION
OF THE NOTES
The Notes offered by this prospectus supplement are senior
debt securities as described in the accompanying
prospectus. This description supplements the description of the
general terms and provisions of the debt securities found in the
accompanying prospectus.
Capitalized terms used and not otherwise defined below or
elsewhere in this prospectus supplement or the accompanying
prospectus are used with the respective meanings given thereto
in the senior indenture, dated as of August 16, 2006,
between CIGNA Corporation and U.S. Bank National
Association (the Trustee), as amended and
supplemented at the closing date of the offering between CIGNA
Corporation and the Trustee (collectively, the Senior
Indenture). In this Description of the Notes
section, when we refer to CIGNA, we,
our, or us, we refer to CIGNA
Corporation not including its consolidated subsidiaries.
The Senior Indenture does not restrict our ability to incur
additional indebtedness, other than certain indebtedness secured
by liens on common stock of our Designated Subsidiaries. The
Senior Indenture contains negative covenants that apply to us;
however, the limitation on liens and the limitation on
consolidation, merger and sale of assets contain important
exceptions. See Description of Debt Securities
Limitations on Liens on Common Stock of Designated
Subsidiaries and Consolidation, Merger
and Sale of Assets in the accompanying prospectus.
General
The 10-Year
Notes initially will be limited to $300,000,000 aggregate
principal amount. The
30-Year
Notes initially will be limited to $300,000,000 aggregate
principal amount.
The 10-Year
Notes and the
30-Year
Notes constitute separate series under the indenture. We may,
without the consent of the holders of either series of Notes,
issue additional Notes of either series in the future, on the
same terms and conditions (except that their issue price may,
and their issue date will, vary) and with the same CUSIP number
as the Notes of such series being offered by this prospectus
supplement; provided, however, that no such
additional Notes may be issued under the Senior Indenture unless
fungible for U.S. federal income tax purposes with the
Notes of such series offered hereby. Any such additional Notes
will be treated as a single series of debt securities with the
associated series of Notes offered hereby for all purposes under
the Senior Indenture.
We will issue the Notes only in fully registered form, without
coupons, in denominations of $2,000 and multiples of $1,000 in
excess thereof.
Interest;
Maturity; No Sinking Fund
The 10-Year
Notes will mature on March 15, 2021, and will bear interest
at a rate of 4.500% per year. Interest on the
10-Year
Notes will accrue from March 7, 2011, or from the most
recent interest payment date to which interest has been paid or
duly provided for. Interest on the
10-Year
Notes is payable semi-annually in arrears on March 15 and
September 15 of each year, beginning September 15,
2011.
The 30-Year
Notes will mature on March 15, 2041, and will bear interest
at a rate of 5.875% per year. Interest on the
30-Year
Notes will accrue from March 7, 2011, or from the most
recent interest payment date to which interest has been paid or
duly provided for. Interest on the
30-Year
Notes is payable semi-annually in arrears on March 15 and
September 15 of each year, beginning September 15,
2011.
The Notes are not subject to any sinking fund provision.
In each case, we:
|
|
|
|
|
will pay interest to the person in whose name a Note is
registered at the close of business on the fifteenth calendar
day prior to the relevant interest payment date;
|
|
|
|
will compute interest on the basis of a
360-day year
consisting of twelve
30-day
months;
|
|
|
|
will make payments on the Notes held in certificated form at the
designated office of the Trustee; and
|
S-6
|
|
|
|
|
may make payments by wire transfer for Notes held in book-entry
form or by check mailed to the address of the person entitled to
the payment as it appears in the note register.
|
If any interest payment date or maturity or redemption date
falls on a day that is not a business day, the required payment
shall be made on the next business day as if it were made on the
date such payment was due, and no interest shall accrue on the
amount so payable from and after such interest payment date or
maturity or redemption date, as the case may be, to such next
business day. Business day means any day other than
a Saturday, Sunday or other day on which banking institutions in
The City of New York are authorized or obligated by law or
executive order to be closed.
Ranking
The Notes will be our senior unsecured and unsubordinated
obligations, and rank equally with all of our existing and
future senior unsecured and unsubordinated indebtedness.
Because a significant part of our operations are conducted
through subsidiaries, a significant portion of our cash flow,
and consequently, our ability to service debt, including the
Notes, is dependent upon the earnings of our subsidiaries and
the transfer of funds by those subsidiaries to us in the form of
dividends or other transfers.
In addition, holders of the Notes will have a junior position to
claims of creditors against our subsidiaries, including policy
holders, trade creditors, debtholders, secured creditors, taxing
authorities, guarantee holders and any preferred shareholders,
except to the extent that we are recognized as a creditor of our
subsidiary. Any claims of the Company as the creditor of its
subsidiary would be subordinate to any security interest in the
assets of such subsidiary and any indebtedness of such
subsidiary senior to that held by us.
In addition to general state law restrictions on payments of
dividends and other distributions to shareholders applicable to
all corporations, HMOs and insurance companies, including some
of CIGNAs indirect subsidiaries, are subject to further
state regulations that, among other things, may require those
companies to maintain certain levels of equity, and restrict the
amount of dividends and other distributions that may be paid to
the Company.
Optional
Redemption
Before the date that is three months prior to the maturity date
for the
10-Year
Notes or before the date that is six months prior to the
maturity date for the
30-Year
Notes, we may redeem the
10-Year
Notes or the
30-Year
Notes, respectively, at any time in whole or from time to time
in part, at a redemption price equal to the greater of:
|
|
|
|
|
100% of the principal amount of the
10-Year
Notes or the
30-Year
Notes to be redeemed, and
|
|
|
|
the sum of the present values of the remaining scheduled
payments of principal and interest (excluding interest accrued
to the redemption date) on the
10-Year
Notes or the
30-Year
Notes being redeemed from the redemption date to the maturity
date discounted to the redemption date on a semi-annual basis
(assuming a
360-day year
consisting of twelve
30-day
months) at the applicable Treasury Rate plus 20 basis
points in the case of the
10-Year
Notes and 25 basis points in the case of the
30-Year
Notes,
|
plus accrued and unpaid interest, if any, on the principal
amount being redeemed to the redemption date.
If the
10-Year
Notes are redeemed on or after the date that is three months
prior to the maturity date for the
10-Year
Notes or if the
30-Year
Notes are redeemed on or after the date that is six months prior
to the maturity date for the
30-Year
Notes, the
10-Year
Notes or the
30-Year
Notes, respectively, will be redeemable, in whole at any time or
in part from time to time, at our option at par plus accrued
interest thereon to but excluding the redemption date.
Comparable Treasury Issue means the United States
Treasury security selected by an Independent Investment
Banker as having a maturity comparable to the remaining
term of the
10-Year
Notes or the
S-7
30-Year
Notes to be redeemed that would be utilized, at the time of
selection and in accordance with customary financial practice,
in pricing new issues of corporate debt securities of comparable
maturity to the remaining term of the
10-Year
Notes or
30-Year
Notes to be redeemed.
Comparable Treasury Price means, with respect to any
redemption date for any
10-Year
Notes or the
30-Year
Notes, the average of all Reference Treasury Dealer Quotations
obtained.
Independent Investment Banker means one of the
Reference Treasury Dealers appointed by the Trustee after
consultation with us.
Reference Treasury Dealer means each of Merrill
Lynch, Pierce, Fenner & Smith Incorporated,
Morgan Stanley & Co. Incorporated and a Primary
Treasury Dealer (as defined below) selected by Wells Fargo
Securities, LLC and their successors. If any Reference Treasury
Dealer ceases to be a primary U.S. government securities
dealer in the United States (a Primary Treasury
Dealer), we will substitute another Primary Treasury
Dealer for that dealer.
Reference Treasury Dealer Quotations means, with
respect to each Reference Treasury Dealer and any redemption
date, the average, as determined by the Trustee, of the bid and
asked prices for the Comparable Treasury Issue (expressed in
each case as a percentage of its principal amount) quoted in
writing to the Trustee by that Reference Treasury Dealer at
5:00 p.m. on the third business day preceding the
redemption date.
Treasury Rate means, with respect to any redemption
date, (1) the yield, under the heading which represents the
average for the immediately preceding week, appearing in the
most recently published statistical release designated
H.15(519) or any successor publication which is
published weekly by the Board of Governors of the Federal
Reserve System and which establishes yields on actively traded
United States Treasury securities adjusted to constant maturity
under the caption Treasury Constant Maturities, for
the maturity corresponding to the Comparable Treasury Issue (if
no maturity is within three months before or after the maturity
date for the
10-Year
Notes or the
30-Year
Notes, yields for the two published maturities most closely
corresponding to the Comparable Treasury Issue will be
determined and the Treasury Rate shall be interpolated or
extrapolated from those yields on a straight line basis,
rounding to the nearest month), or (2) if the release
referred to in clause (1) (or any successor release) is not
published during the week preceding the calculation date or does
not contain the yields referred to above, the rate per annum
equal to the semi-annual equivalent yield to maturity of the
Comparable Treasury Issue, calculated using a price for the
Comparable Treasury Issue (expressed as a percentage of its
principal amount) equal to the Comparable Treasury Price for
that redemption date.
The Treasury Rate will be calculated on the third business day
preceding the redemption date.
Notice of any redemption will be mailed at least 15 days
but no more than 60 days before the redemption date to each
holder of
10-Year
Notes or the
30-Year
Notes to be redeemed.
Unless we default in payment of the redemption price, interest
will cease to accrue on the
10-Year
Notes or the
30-Year
Notes or portion of the
10-Year
Notes or the
30-Year
Notes called for redemption on and after the redemption date.
Change of
Control Offer
If a Change of Control Triggering Event (as defined below)
occurs with respect to the
10-Year
Notes or the
30-Year
Notes, unless we have exercised our right to redeem the
10-Year
Notes or
30-Year
Notes, as applicable, in full, as described under Optional
Redemption above, we will make an offer to each holder
(the Change of Control Offer) to repurchase any and
all of such holders
10-Year
Notes or
30-Year
Notes, as applicable, at a repurchase price in cash equal to
101% of the aggregate principal amount of the
10-Year
Notes or
30-Year
Notes, as applicable, repurchased plus accrued and unpaid
interest, if any, thereon, to the date of repurchase (the
Change of Control Payment).
Within 30 days following any Change of Control Triggering
Event, we will be required to mail a notice to holders of
10-Year
Notes or
30-Year
Notes, as applicable, describing the transaction or transactions
that
S-8
constitute the Change of Control Triggering Event and offering
to repurchase the
10-Year
Notes or
30-Year
Notes, as applicable, on the date specified in the notice, which
date will be no less than 30 days and no more than
60 days from the date such notice is mailed (the
Change of Control Payment Date), pursuant to the
procedures required by the
10-Year
Notes or
30-Year
Notes, as applicable, and described in such notice.
We must comply with the requirements of
Rule 14e-1
under the Exchange Act, and any other securities laws and
regulations thereunder to the extent those laws and regulations
are applicable in connection with the repurchase of the
10-Year
Notes or
30-Year
Notes, as applicable, as a result of a Change of Control
Triggering Event. To the extent that the provisions of any
securities laws or regulations conflict with the Change of
Control repurchase provisions of the
10-Year
Notes or
30-Year
Notes, as applicable, we will be required to comply with the
applicable securities laws and regulations and will not be
deemed to have breached our obligations under the Change of
Control repurchase provisions of the
10-Year
Notes or
30-Year
Notes, as applicable, by virtue of such conflicts. We will not
be required to offer to repurchase the
10-Year
Notes or
30-Year
Notes, as applicable, upon the occurrence of a Change of Control
Triggering Event if a third party makes such an offer in the
manner, at the times and otherwise in compliance with the
requirements for an offer made by us and the third party
repurchases on the applicable date all
10-Year
Notes or
30-Year
Notes, as applicable, properly tendered and not withdrawn under
its offer; provided that for all purposes of the
10-Year
Notes or
30-Year
Notes and the Senior Indenture, a failure by such third party to
comply with the requirements of such offer and to complete such
offer shall be treated as a failure by us to comply with our
obligations to offer to purchase the
10-Year
Notes or
30-Year
Notes, as applicable, unless we promptly make an offer to
repurchase the
10-Year
Notes or
30-Year
Notes, as applicable, at 101% of the principal amount thereof
plus accrued and unpaid interest, if any, thereon, to the date
of repurchase, which shall be no later than 30 days after
the third partys scheduled Change of Control Payment Date.
On the Change of Control Payment Date, we will be required, to
the extent lawful, to:
|
|
|
|
|
accept or cause a third party to accept for payment all
10-Year
Notes or
30-Year
Notes, as applicable, properly tendered pursuant to the Change
of Control Offer;
|
|
|
|
deposit or cause a third party to deposit with the paying agent
an amount equal to the Change of Control Payment in respect of
all 10-Year
Notes or
30-Year
Notes, as applicable, properly tendered; and
|
|
|
|
deliver or cause to be delivered to the Trustee the
10-Year
Notes or
30-Year
Notes, as applicable, properly accepted, together with an
officers certificate stating the principal amount of
10-Year
Notes or
30-Year
Notes, as applicable, being purchased.
|
The definition of Change of Control includes a phrase relating
to the direct or indirect sale, lease, transfer, conveyance or
other disposition of all or substantially all of the
properties or assets of CIGNA and its subsidiaries taken as a
whole. Although there is a limited body of case law interpreting
the phrase substantially all, there is no precise,
established definition of the phrase under applicable law.
Accordingly, the applicability of the requirement that we offer
to repurchase the
10-Year
Notes or
30-Year
Notes as a result of a sale, lease, transfer, conveyance or
other disposition of less than all of the assets of CIGNA and
its subsidiaries taken as a whole to another Person (as defined
in the Senior Indenture) or group may be uncertain.
For purposes of the foregoing discussion of the applicable
Change of Control provisions, the following definitions are
applicable:
Below Investment Grade Rating Event means with
respect to the
10-Year
Notes or
30-Year
Notes, as applicable, such Notes are rated below all Investment
Grade Ratings by at least two of the three Rating Agencies on
any date from the earlier of (1) the occurrence of a Change
of Control and (2) public notice of our intention to effect
a Change of Control, in each case until the end of the
60-day
period following public notice of the occurrence of the Change
of Control; provided, however, that if
(i) during such
60-day
period one or more Rating Agencies has publicly announced that
it is considering the possible downgrade of the
10-Year
Notes or
30-Year
Notes, as applicable, and (ii) a downgrade by each of the
Rating Agencies that has made such an announcement would result
in a Below Investment Grade Rating Event, then such
60-day
period
S-9
shall be extended for such time as the rating of the
10-Year
Notes or
30-Year
Notes, as applicable, by any such Rating Agency remains under
publicly announced consideration for possible downgrade to a
rating below an Investment Grade Rating and a downgrade by such
Rating Agency to a rating below an Investment Grade Rating could
cause a Below Investment Grade Rating Event. Notwithstanding the
foregoing, a rating event otherwise arising by virtue of a
particular reduction in rating will not be deemed to have
occurred in respect of a particular Change of Control (and thus
will not be deemed a rating event for purposes of the definition
of Change of Control Triggering Event) if the rating agencies
making the reduction in rating to which this definition would
otherwise apply do not announce or publicly confirm or inform
the Trustee in writing at our or its request that the reduction
was the result, in whole or in part, of any event or
circumstance comprised of or arising as a result of, or in
respect of, the applicable Change of Control (whether or not the
applicable Change of Control has occurred at the time of the
rating event).
Change of Control means the occurrence of any of the
following:
|
|
|
|
(1)
|
direct or indirect sale, transfer, conveyance or other
disposition (other than by way of merger or consolidation), in
one or a series of related transactions, of all or substantially
all of the properties or assets of CIGNA and its subsidiaries
taken as a whole to any person (as that term is used
in Section 13(d)(3) of the Exchange Act) other than to
CIGNA or one of its subsidiaries;
|
|
|
(2)
|
the consummation of any transaction (including, without
limitation, any merger or consolidation) the result of which is
that any person (as that term is used in Section
13(d)(3) of the Exchange Act) other than CIGNA or one of its
subsidiaries becomes the beneficial owner, directly or
indirectly, of more than 50% of the then outstanding number of
shares of CIGNAs voting stock; or
|
|
|
(3)
|
the first day on which a majority of the members of CIGNAs
Board of Directors are not Continuing Directors;
|
provided, however, that a transaction will not be
deemed to involve a Change of Control if (A) we become a
wholly owned subsidiary of a holding company and (B)(x) the
holders of the voting stock of such holding company immediately
following that transaction are substantially the same as the
holders of CIGNAs voting stock immediately prior to that
transaction or (y) immediately following that transaction
no Person is the beneficial owner, directly or indirectly, of
more than 50% of the voting stock of such holding company. For
purposes of this definition, voting stock means
capital stock of any class or kind the holders of which are
ordinarily, in the absence of contingencies, entitled to vote
for the election of directors (or persons performing similar
functions) of CIGNA, even if the right to vote has been
suspended by the happening of such a contingency.
Change of Control Triggering Event means the
occurrence of both a Change of Control and a Below Investment
Grade Rating Event.
Continuing Director means, as of any date of
determination, any member of the Board of Directors of CIGNA who
(1) was a member of the Board of Directors of CIGNA on the
date of the issuance of the Notes; or (2) was nominated for
election or elected to the Board of Directors of CIGNA with the
approval of a majority of the Continuing Directors who were
members of such Board of Directors of CIGNA at the time of such
nomination or election (either by specific vote or by approval
of CIGNAs proxy statement in which such member was named
as a nominee for election as a director).
Fitch means Fitch Ratings Inc. and its successors.
Investment Grade Rating means a rating by
Moodys equal to or higher than Baa3 (or the equivalent
under a successor rating category of Moodys), a rating by
S&P equal to or higher than BBB- (or the equivalent under
any successor rating category of S&P), a rating by Fitch
equal to or higher than BBB- (or the equivalent under any
successor rating category of Fitch), and the equivalent
investment grade credit rating from any replacement rating
agency or rating agencies selected by us under the circumstances
permitting us to select a replacement agency and in the manner
for selecting a replacement agency, in each case as set forth in
the definition of Rating Agencies.
Moodys means Moodys Investors Service,
Inc. and its successors.
S-10
Rating Agencies means (1) Moodys,
S&P and Fitch; and (2) if any or all of Moodys,
S&P or Fitch ceases to rate the
10-Year
Notes or
30-Year
Notes or fails to make a rating of the
10-Year
Notes or
30-Year
Notes publicly available for reasons outside of our control, a
nationally recognized statistical rating
organization within the meaning of Section 3(a)(62)
of the Exchange Act, that we select (pursuant to a resolution of
the CIGNA Board of Directors) as a replacement agency for any of
Moodys, S&P or Fitch, or all of them, as the case may
be.
S&P means Standard & Poors
Ratings Services, a division of The McGraw-Hill Companies, Inc.,
and its successors.
Defeasance
and Covenant Defeasance
The full defeasance and covenant defeasance provisions of the
Senior Indenture described in the accompanying prospectus under
Description of Debt Securities Defeasance and
Covenant Defeasance will apply to the Notes.
Global
Notes; Book-Entry System
Global
Notes
The Notes will be issued initially in book-entry form and will
be represented by one or more global notes in fully registered
form without interest coupons which will be deposited with the
Trustee as custodian for The Depository Trust Company,
which we refer to as DTC, and registered in the name
of Cede & Co. or another nominee designated by DTC.
Except as set forth below, the global notes may be transferred,
in whole and not in part, only to DTC or another nominee of DTC
or to a successor of DTC or its nominee. Beneficial interests in
the global notes may not be exchanged for certificated notes
except in the limited circumstances described below.
All interests in the global notes will be subject to the rules
and procedures of DTC.
Investors in the global notes may hold their interests therein
directly through DTC, if they are participants in such system or
indirectly through such organizations (including Euroclear and
Clearstream) which are participants in such system. Euroclear
and Clearstream will hold interests in the global notes on
behalf of their participants through customers securities
accounts in their respective names on the books of their
respective depositories, which are Euroclear Bank,
S.A./N.V., as operator of Euroclear, and Clearstream
Banking, S.A., as operator of Clearstream. The depositaries,
in turn, will hold interests in the global notes in
customers securities accounts in the depositaries
names on the books of DTC. All interests in a global note,
including those held through Euroclear or Clearstream, will be
subject to the procedures and requirements of DTC. Those
interests held through Euroclear or Clearstream will also be
subject to the procedures and requirements of those systems.
Certain
Book-Entry Procedures for the Global Notes
The descriptions of the operations and procedures of DTC set
forth below are provided solely as a matter of convenience.
These operations and procedures are solely within the control of
DTC and are subject to change by DTC from time to time. Neither
we, the Trustee, nor the underwriters take any responsibility
for these operations or procedures, and investors are urged to
contact DTC or its participants directly to discuss these
matters.
DTC has advised us that it is:
|
|
|
|
|
a limited-purpose trust company organized under the laws of the
State of New York;
|
|
|
|
a banking organization within the meaning of the New
York Banking Law;
|
|
|
|
a member of the Federal Reserve System;
|
S-11
|
|
|
|
|
a clearing corporation within the meaning of the New
York Uniform Commercial Code, as amended; and
|
|
|
|
a clearing agency registered pursuant to
Section 17A of the Exchange Act.
|
DTC was created to hold securities for its participants and to
facilitate the clearance and settlement of securities
transactions between participants through electronic book-entry
changes to the accounts of its participants, thereby eliminating
the need for physical transfer and delivery of certificates.
DTCs participants include securities brokers and dealers
(including one or more of the underwriters), banks and trust
companies, clearing corporations and certain other
organizations. Indirect access to DTCs system is also
available to other entities such as banks, brokers, dealers and
trust companies, which we refer to collectively as the
indirect participants, that clear through or
maintain a custodial relationship with a participant either
directly or indirectly. Investors who are not participants may
beneficially own securities held by or on behalf of DTC only
through participants or indirect participants.
We expect that, pursuant to procedures established by DTC:
|
|
|
|
|
upon deposit of each global note, DTC will credit, on its
book-entry registration and transfer system, the accounts of
participants designated by the underwriters with an interest in
the global note; and
|
|
|
|
ownership of beneficial interests in the global notes will be
shown on, and the transfer of ownership of beneficial interests
in the global notes will be effected only through, records
maintained by DTC (with respect to the interests of
participants) and the participants and the indirect participants
(with respect to the interests of persons other than
participants).
|
The laws of some jurisdictions may require that some purchasers
of securities take physical delivery of those securities in
definitive form. Accordingly, the ability to transfer beneficial
interests in the Notes represented by a global note to those
persons may be limited. In addition, because DTC can act only on
behalf of its participants, who in turn act on behalf of persons
who hold interests through participants, the ability of a person
holding a beneficial interest in a global note to pledge or
transfer that interest to persons or entities that do not
participate in DTCs system, or to otherwise take actions
in respect of that interest, may be affected by the lack of a
physical security in respect of that interest.
So long as DTC or its nominee is the registered owner of a
global note, DTC or that nominee, as the case may be, will be
considered the sole legal owner or holder of the Notes
represented by that global note for all purposes of the Notes
and the Senior Indenture. Except as provided below, owners of
beneficial interests in a global note will not be entitled to
have the Notes represented by that global note registered in
their names, will not receive or be entitled to receive physical
delivery of certificated Notes and will not be considered the
owners or holders of the Notes represented by that beneficial
interest under the Senior Indenture for any purpose, including
with respect to the giving of any direction, instruction or
approval to the Trustee. Accordingly, each holder owning a
beneficial interest in a global note must rely on the procedures
of DTC and, if that holder is not a participant or an indirect
participant, on the procedures of the participant through which
that holder owns its interest, to exercise any rights of a
holder of Notes under the Senior Indenture or that global note.
We understand that under existing industry practice, in the
event that we request any action of holders of Notes, or a
holder that is an owner of a beneficial interest in a global
note desires to take any action that DTC, as the holder of that
global note, is entitled to take, DTC would authorize the
participants to take that action and the participants would
authorize holders owning through those participants to take that
action or would otherwise act upon the instruction of those
holders. Neither we nor the Trustee will have any responsibility
or liability for any aspect of the records relating to or
payments made on account of Notes by DTC or for maintaining,
supervising or reviewing any records of DTC relating to the
Notes.
Payments with respect to the principal of and interest on a
global note will be payable by the Trustee to or at the
direction of DTC or its nominee in its capacity as the
registered holder of the global note under the Senior Indenture.
Under the terms of the Senior Indenture, we and the Trustee may
treat the persons in whose names the Notes, including the global
notes, are registered as the owners thereof for the purpose of
receiving payment thereon and for any and all other purposes
whatsoever. Accordingly, neither we nor the Trustee has or will
have any responsibility or liability for the payment of those
amounts to owners of beneficial interests
S-12
in a global note. Payments by the participants and the indirect
participants to the owners of beneficial interests in a global
note will be governed by standing instructions and customary
industry practice and will be the responsibility of the
participants and indirect participants and not of DTC.
Although DTC has agreed to the foregoing procedures to
facilitate transfers of interests in the global notes among
participants in DTC, it is under no obligation to perform or to
continue to perform those procedures, and those procedures may
be discontinued at any time. Neither we nor the Trustee will
have any responsibility for the performance by DTC or its
participants or indirect participants of their respective
obligations under the rules and procedures governing their
operations.
Clearstream and Euroclear have provided us with the following
information and neither we nor the underwriters take any
responsibility for its accuracy:
Clearstream. Clearstream is incorporated under
the laws of Luxembourg as a professional depositary. Clearstream
holds securities for its participating organizations and
facilitates the clearance and settlement of securities
transactions between Clearstream participants through electronic
book-entry changes in accounts of Clearstream participants,
thereby eliminating the need for physical movement of
certificates. Clearstream provides to Clearstream participants,
among other things, services for safekeeping, administration,
clearance and settlement of internationally traded securities
and securities lending and borrowing. Clearstream interfaces
with domestic securities markets in several countries. As a
professional depositary, Clearstream is subject to regulation by
the Luxembourg Commission for the Supervision of the Financial
Sector (Commission de Surveillance du Secteur Financier).
Clearstream participants include underwriters, securities
brokers and dealers, banks, trust companies, clearing
corporations and certain other organizations and may include the
underwriters. Clearstreams U.S. participants are
limited to securities brokers and dealers and banks. Indirect
access to Clearstream is also available to others, such as
banks, brokers, dealers and trust companies that clear through
or maintain a custodial relationship with a Clearstream
participant either directly or indirectly.
Distributions with respect to Notes held beneficially through
Clearstream will be credited to cash accounts of Clearstream
participants in accordance with its rules and procedures, to the
extent received by the U.S. depositary for Clearstream.
Euroclear. Euroclear was created in 1968 to
hold securities for participants of Euroclear and to clear and
settle transactions between Euroclear participants through
simultaneous electronic book-entry delivery against payment,
thereby eliminating the need for physical movement of
certificates and any risk from lack of simultaneous transfers of
securities and cash. Euroclear performs various other services,
including securities lending and borrowing and interacts with
domestic markets in several countries. Euroclear is operated by
Euroclear Bank S.A/N.V. under contract with Euroclear plc, a
U.K. corporation. All operations are conducted by the Euroclear
operator, and all Euroclear securities clearance accounts and
Euroclear cash accounts are accounts with the Euroclear
operator, not Euroclear plc. Euroclear plc establishes policy
for Euroclear on behalf of Euroclear participants. Euroclear
participants include banks, including central banks, securities
brokers and dealers and other professional financial
intermediaries and may include the underwriters. Indirect access
to Euroclear is also available to other firms that clear through
or maintain a custodial relationship with a Euroclear
participant, either directly or indirectly.
The Euroclear operator is a Belgian bank. As such it is
regulated by the Belgian Banking and Finance Commission.
Securities clearance accounts and cash accounts with the
Euroclear operator are governed by the Terms and Conditions
Governing Use of Euroclear and the related Operating Procedures
of the Euroclear System, and applicable Belgian law
(collectively, the Terms and Conditions). The Terms
and Conditions govern transfers of securities and cash within
Euroclear, withdrawals of securities and cash from Euroclear,
and receipts of payments with respect to securities in
Euroclear. All securities in Euroclear are held on a fungible
basis without attribution of specific certificates to specific
clearance accounts. The Euroclear operator acts under the Terms
and Conditions only on behalf of Euroclear participants and has
no record of or relationship with persons holding through
Euroclear participants.
S-13
Distributions with respect to Notes held beneficially through
Euroclear will be credited to the cash accounts of Euroclear
participants in accordance with the Terms and Conditions, to the
extent received by the U.S. depositary for Euroclear.
Euroclear has further advised us that investors who acquire,
hold and transfer interests in the Notes by book-entry through
accounts with the Euroclear operator or any other securities
intermediary are subject to the laws and contractual provisions
governing their relationship with their intermediary, as well as
the laws and contractual provisions governing the relationship
between such an intermediary and each other intermediary, if
any, standing between themselves and the global securities
certificates.
Global Clearance and Settlement
Procedures. Initial settlement for the Notes will
be made in immediately available funds. Secondary market trading
between DTC participants will occur in the ordinary way in
accordance with DTC rules and will be settled in immediately
available funds using DTCs Same Day Funds Settlement
System. Secondary market trading between Clearstream
participants
and/or
Euroclear participants will occur in the ordinary way in
accordance with the applicable rules and operating procedures of
Clearstream and Euroclear and will be settled using the
procedures applicable to conventional eurobonds in immediately
available funds.
Cross market transfers between persons holding directly or
indirectly through DTC, on the one hand, and directly or
indirectly through Clearstream participants or Euroclear
participants, on the other, will be effected through DTC in
accordance with DTC rules on behalf of the relevant European
international clearing system by its U.S. depositary;
however, such cross market transactions will require delivery of
instructions to the relevant European international clearing
system by the counterparty in such system in accordance with its
rules and procedures and within its established deadlines
(European time). The relevant European international clearing
system will, if the transaction meets its settlement
requirements, deliver instructions to its U.S. depositary
to take action to effect final settlement on its behalf by
delivering or receiving Notes through DTC, and making or
receiving payment in accordance with normal procedures for same
day funds settlement applicable to DTC. Clearstream participants
and Euroclear participants may not deliver instructions directly
to their respective U.S. depositaries.
Because of time zone differences, credits of Notes received
through Clearstream or Euroclear as a result of a transaction
with a DTC participant will be made during subsequent securities
settlement processing and dated the business day following the
DTC settlement date. Such credits or any transactions in such
Notes settled during such processing will be reported to the
relevant Euroclear participants or Clearstream participants on
such business day. Cash received in Clearstream or Euroclear as
a result of sales of Notes by or through a Clearstream
participant or a Euroclear participant to a DTC participant will
be received with value on the DTC settlement date but will be
available in the relevant Clearstream or Euroclear cash account
only as of the business day following settlement in DTC.
Although DTC, Clearstream and Euroclear have agreed to the
foregoing procedures in order to facilitate transfers of Notes
among participants of DTC, Clearstream and Euroclear, they are
under no obligation to perform or continue to perform such
procedures and such procedures may be modified or discontinued
at any time. Neither we nor the paying agent will have any
responsibility for the performance by DTC, Euroclear or
Clearstream or their respective direct or indirect participants
of their obligations under the rules and procedures governing
their operations.
We obtained the information in this section and elsewhere in
this prospectus supplement concerning DTC and its book-entry
system, Clearstream and Euroclear from sources that we believe
are reliable, but we take no responsibility for the accuracy of
any of this information.
S-14
Certificated
Notes
We will issue certificated notes in fully registered form to
each person that DTC identifies as the beneficial owner of the
Notes represented by the global securities upon surrender by DTC
of the global securities only if:
|
|
|
|
|
DTC notifies us that it is no longer willing or able to act as a
depository for the global securities, and we have not appointed
a successor depository within 90 days of that notice;
|
|
|
|
an event of default has occurred and is continuing; or
|
|
|
|
we determine not to have the Notes represented by a global
security.
|
Neither we nor the Trustee will be liable for any delay by DTC,
its nominee or any direct or indirect participant in identifying
the beneficial owners of the related Notes. We and the Trustee
may conclusively rely on, and will be protected in relying on,
instructions from DTC or its nominee for all purposes, including
with respect to the registration and delivery, and the
respective principal amounts, of the Notes to be issued in
certificated form.
S-15
UNITED
STATES FEDERAL INCOME TAX CONSIDERATIONS
In the opinion of Davis Polk & Wardwell LLP, the
following are the material U.S. federal income tax
considerations relevant to ownership and disposition of the
Notes. This discussion only applies to Notes that meet both of
the following conditions:
|
|
|
|
|
they are purchased by those initial holders who purchase Notes
at the issue price, which will equal the first price
to the public (not including bond houses, brokers or similar
persons or organizations acting in the capacity of underwriters,
placement agents or wholesalers) at which a substantial amount
of the Notes is sold for money; and
|
|
|
|
they are held as capital assets.
|
This discussion does not describe all of the tax consequences
that may be relevant to holders in light of their particular
circumstances or to holders subject to special rules, such as:
|
|
|
|
|
certain financial institutions;
|
|
|
|
dealers in securities;
|
|
|
|
persons holding Notes as part of a straddle or
integrated transaction;
|
|
|
|
U.S. Holders (as defined below) whose functional currency
is not the U.S. dollar;
|
|
|
|
partnerships or other entities classified as partnerships for
U.S. federal income tax purposes;
|
|
|
|
persons subject to the alternative minimum tax; or
|
|
|
|
tax-exempt organizations.
|
This summary is based on the Internal Revenue Code of 1986 (the
Code), as amended to the date hereof, administrative
pronouncements, judicial decisions and final, temporary and
proposed Treasury Regulations, changes to any of which
subsequent to the date of this prospectus supplement may affect
the tax consequences described herein. Persons considering the
purchase of Notes are urged to consult their tax advisers with
regard to the application of the U.S. federal income tax
laws to their particular situations as well as any tax
consequences arising under the laws of any state, local or
foreign taxing jurisdiction.
Tax
Consequences to U.S. Holders
As used herein, the term U.S. Holder means a
beneficial owner of a Note that is for U.S. federal income
tax purposes:
|
|
|
|
|
a citizen or resident of the United States;
|
|
|
|
a corporation, or other entity taxable as a corporation for
U.S. federal income tax purposes, created or organized in
or under the laws of the United States or of any political
subdivision thereof; or
|
|
|
|
an estate or trust the income of which is subject to
U.S. federal income taxation regardless of its source.
|
The term U.S. Holder also includes certain
former citizens and residents of the United States.
Payments
of Interest
The Notes are expected to be issued without original issue
discount for U.S. federal income tax purposes. Accordingly,
interest paid on a Note will be taxable to a U.S. Holder as
ordinary interest income at the time it accrues or is received
in accordance with the holders method of accounting for
federal income tax purposes.
Sale,
Exchange or Retirement of the Notes
Upon the sale, exchange or retirement of a Note, a
U.S. Holder will recognize taxable gain or loss equal to
the difference between the amount realized on the sale, exchange
or retirement and the holders adjusted tax
S-16
basis in the Note (generally, its cost). For these purposes, the
amount realized does not include any amount attributable to
accrued interest which will be treated as interest as described
under Payments of Interest above.
Gain or loss realized on the sale, exchange or retirement of a
Note will be capital gain or loss and will be long-term capital
gain or loss if at the time of the sale, exchange or retirement
the Note has been held for more than one year.
Backup
Withholding and Information Reporting
Information returns will generally be filed with the Internal
Revenue Service (the IRS) in connection with
payments on the Notes and the proceeds from a sale or other
disposition of the Notes. A U.S. Holder will be subject to
U.S. backup withholding on these payments if the
U.S. Holder fails to provide its taxpayer identification
number to the paying agent and comply with certain certification
procedures or otherwise establish an exemption from backup
withholding. The amount of any backup withholding from a payment
to a U.S. Holder will be allowed as a credit against the
U.S. Holders federal income tax liability and may
entitle the U.S. Holder to a refund, provided that the
required information is timely furnished to the IRS.
Tax
Consequences to
Non-U.S.
Holders
As used herein, the term
Non-U.S. Holder
means a beneficial owner of a Note that is for U.S. federal
income tax purposes:
|
|
|
|
|
an individual who is classified as a nonresident for
U.S. federal income tax purposes;
|
|
|
|
a foreign corporation; or
|
|
|
|
a foreign estate or trust.
|
The term
Non-U.S. Holder
does not include an individual present in the United States for
183 days or more in the taxable year of disposition of a
Note. Such a holder is urged to consult his or her tax adviser
regarding the U.S. federal income tax consequences of the
disposition of a Note.
Subject to the discussion below concerning backup withholding:
|
|
|
|
|
payments of principal and interest on the Notes by us or any
paying agent to any
Non-U.S. Holder
will not be subject to U.S. federal withholding tax,
provided that, in the case of interest,
|
|
|
|
|
|
the beneficial owner does not own, actually or constructively,
10% or more of the total combined voting power of all classes of
our stock entitled to vote and is not a controlled foreign
corporation related, directly or indirectly, to us through stock
ownership; and
|
|
|
|
the certification requirement described below has been fulfilled
with respect to the beneficial owner, as discussed below.
|
|
|
|
|
|
a
Non-U.S. Holder
of a Note will not be subject to U.S. federal income tax
with respect to gain realized on the disposition of a Note
unless the gain is effectively connected with the conduct by the
holder of a trade or business in the United States, subject to
an applicable income tax treaty providing otherwise.
|
The certification requirement described above generally will be
satisfied if the
Non-U.S. Holder
certifies on IRS
Form W-8BEN,
under penalties of perjury, that it is not a United States
person.
If a
Non-U.S. Holder
of a Note is engaged in a trade or business in the United
States, and if income or gain on the Note is effectively
connected with the conduct of this trade or business, the
Non-U.S. Holder,
although exempt from the withholding tax referred to above, will
generally be taxed in the same manner as a U.S. Holder (see
Tax Consequences to U.S. Holders,
above), subject to an applicable income tax treaty providing
otherwise, except that the holder will, in the case of interest,
be required to provide a properly executed IRS
Form W-8ECI
in order to claim an exemption from withholding. These holders
should consult
S-17
their tax advisers with respect to other U.S. tax
consequences of the ownership and disposition of Notes,
including the possible imposition of a 30% branch profits tax if
the holder is a corporation.
Backup
Withholding and Information Reporting
Information returns will generally be filed with the IRS in
connection with interest payments on the Notes. Unless the
Non-U.S. Holder
complies with certification procedures to establish that it is
not a U.S. person, information returns may be filed with
the IRS in connection with the proceeds from a disposition of
the Notes and the
Non-U.S. Holder
may be subject to backup withholding with respect to payments on
the Notes or on the proceeds from a disposition of the Notes.
Compliance with the certification procedures required to claim
the exemption from withholding tax on interest referred to above
will satisfy the certification requirements necessary to avoid
backup withholding as well. The amount of any backup withholding
from a payment to a
Non-U.S. Holder
will be allowed as a credit against the
Non-U.S. Holders
federal income tax liability and may entitle the
Non-U.S. Holder
to a refund, provided that the required information is timely
furnished to the IRS.
S-18
UNDERWRITING
Merrill Lynch, Pierce, Fenner & Smith Incorporated,
Morgan Stanley & Co. Incorporated and Wells Fargo
Securities, LLC are acting as book-running managers of the
offering and as representatives of the underwriters named below.
Subject to the terms and conditions stated in the underwriting
agreement dated the date of this prospectus supplement, each
underwriter named below has agreed to purchase, and we have
agreed to sell to that underwriter, the principal amount of
Notes set forth opposite the underwriters name.
|
|
|
|
|
|
|
|
|
|
|
Principal Amount of
|
|
|
Principal Amount of
|
|
Underwriter
|
|
10-Year Notes
|
|
|
30-Year Notes
|
|
|
Merrill Lynch, Pierce, Fenner & Smith Incorporated
|
|
$
|
60,000,000
|
|
|
$
|
60,000,000
|
|
Morgan Stanley & Co. Incorporated
|
|
|
60,000,000
|
|
|
|
60,000,000
|
|
Wells Fargo Securities, LLC
|
|
|
60,000,000
|
|
|
|
60,000,000
|
|
Barclays Capital Inc.
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
BNY Mellon Capital Markets, LLC
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
Citigroup Global Markets Inc.
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
Deutsche Bank Securities Inc.
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
Goldman, Sachs & Co.
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
HSBC Securities (USA) Inc.
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
J.P. Morgan Securities LLC
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
Mitsubishi UFJ Securities (USA), Inc.
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
UBS Securities LLC
|
|
|
12,000,000
|
|
|
|
12,000,000
|
|
Mizuho Securities USA Inc.
|
|
|
3,000,000
|
|
|
|
3,000,000
|
|
PNC Capital Markets LLC
|
|
|
3,000,000
|
|
|
|
3,000,000
|
|
SMBC Nikko Capital Markets Limited
|
|
|
3,000,000
|
|
|
|
3,000,000
|
|
SunTrust Robinson Humphrey, Inc.
|
|
|
3,000,000
|
|
|
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
300,000,000
|
|
|
$
|
300,000,000
|
|
|
|
|
|
|
|
|
|
|
The underwriting agreement provides that the obligations of the
underwriters to purchase the Notes included in this offering are
subject to the receipt of legal opinions by counsel covering the
validity of the Notes and to other conditions. The underwriters
are obligated to purchase all the Notes if they purchase any of
the Notes. The offering of the Notes by the underwriters is
subject to receipt and acceptance and subject to the
underwriters right to reject any order in whole or in part.
The underwriters propose to offer some of the Notes directly to
the public at the offering price set forth on the cover page of
this prospectus supplement and may offer some of the Notes to
dealers at the offering price less a concession not to exceed
0.40% of the principal amount of the 10-Year Notes and 0.50% of
the principal amount of the 30-Year Notes. The underwriters may
allow, and dealers may reallow, a concession on sales to other
dealers not to exceed 0.25% of the principal amount of the
10-Year Notes and 0.25% of the principal amount of the 30-Year
Notes. After the initial offering of the Notes to the public,
the representatives may change the offering price and other
selling terms.
The Notes are a new issue of securities with no established
trading market. The Notes will not be listed on any securities
exchange or automated quotation system. We have been advised by
the underwriters that they intend to make a market in the Notes,
but the underwriters are not obligated to do so and may
discontinue market making at any time without notice. We can
give no assurance as to the liquidity of, or the trading market
for, the Notes.
S-19
The following table shows the underwriting discounts and
commissions that we are to pay to the underwriters in connection
with this offering (expressed as a percentage of the principal
amount of the Notes).
|
|
|
|
|
|
|
Paid by CIGNA
|
|
|
Corporation
|
|
Per 10-Year
Note
|
|
|
0.650
|
%
|
Per 30-Year
Note
|
|
|
0.875
|
%
|
In connection with the offering, the representatives may
purchase and sell Notes in the open market. These transactions
may include over-allotment, syndicate covering transactions and
stabilizing transactions. Over-allotment involves syndicate
sales of Notes in excess of the principal amount of Notes to be
purchased by the underwriters in the offering, which creates a
syndicate short position. Syndicate covering transactions
involve purchases of the Notes in the open market after the
distribution has been completed in order to cover syndicate
short positions. Stabilizing transactions consist of certain
bids or purchases of Notes made for the purpose of preventing or
postponing a decline in the market price of the Notes while the
offering is in progress.
The representatives also may impose a penalty bid. Penalty bids
permit the underwriters to reclaim a selling concession from a
syndicate member when the representative responsible for
stabilizing activities on behalf of the syndicate, in covering
syndicate short positions or making stabilizing purchases,
repurchases Notes originally sold by that syndicate member.
Any of these activities may have the effect of preventing or
retarding a decline in the market price of the Notes. They may
also cause the price of the Notes to be higher than the price
that otherwise would exist in the open market in the absence of
these transactions. The representatives may conduct these
transactions in the
over-the-counter
market or otherwise. If the representatives commence any of
these transactions, they may discontinue them at any time
without notice.
We have agreed to indemnify the several underwriters against
certain liabilities, including liabilities under the Securities
Act of 1933, or to contribute to payments the underwriters may
be required to make because of any of those liabilities.
The Company estimates that its share of the total expenses of
the offering, excluding underwriting discounts, will be
approximately $1,200,000.
The underwriters and their respective affiliates are full
service financial institutions engaged in various activities,
which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment
research, principal investment, hedging, financing and brokerage
activities. The underwriters and their affiliates have engaged
in, and may in the future engage in, investment banking,
commercial banking and other commercial dealings in the ordinary
course of business with us. They have received, and in the
future may receive, customary fees and commissions for these
transactions. In the ordinary course of their various business
activities, the underwriters and their respective affiliates may
make or hold a broad array of investments and actively trade
debt and equity securities (or related derivative securities)
and financial instruments (including bank loans) for their own
account and for the accounts of their customers, and such
investment and securities activities may involve securities
and/or
instruments of the issuer. The underwriters and their respective
affiliates may also make investment recommendations
and/or
publish or express independent research views in respect of such
securities or instruments and may at any time hold, or recommend
to clients that they acquire, long
and/or short
positions in such securities and instruments.
SMBC Nikko Capital Markets Limited is not a U.S. registered
broker-dealer and, therefore, intends to participate in the
offering outside of the United States and, to the extent that
the offering is within the United States, as facilitated by an
affiliated U.S. registered broker-dealer, SMBC Nikko
Securities America, Inc. (SMBC Nikko-SI), as
permitted under applicable law. To that end, SMBC Nikko Capital
Markets Limited and SMBC Nikko-SI have entered into an agreement
pursuant to which SMBC Nikko-SI provides certain advisory
and/or other
services with respect to this offering. In return for the
provision of such services by SMBC Nikko-SI, SMBC Nikko Capital
Markets Limited will pay to SMBC Nikko-SI a mutually agreed-fee.
S-20
Selling
Restrictions
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a
Relevant Member State), each underwriter has
represented and agreed that with effect from and including the
date on which the Prospectus Directive is implemented in that
Relevant Member State (the Relevant Implementation
Date) it has not made and will not make an offer of Notes
which are the subject of the offering contemplated by this
prospectus supplement to the public in that Relevant Member
State other than:
|
|
|
|
(a)
|
to any legal entity which is a qualified investor as defined in
the Prospectus Directive;
|
|
|
(b)
|
to fewer than 100 or, if the Relevant Member State has
implemented the relevant provision of the 2010 PD Amending
Directive, 150, natural or legal persons (other than qualified
investors as defined in the Prospectus Directive), as permitted
under the Prospectus Directive, subject to obtaining the prior
consent of the book-running manager for any such offer; or
|
|
|
(c)
|
in any other circumstances falling within Article 3(2) of
the Prospectus Directive,
|
provided that no such offer of Notes shall require the us or any
underwriter to publish a prospectus pursuant to Article 3
of the Prospectus Directive.
For the purposes of this provision, the expression an offer of
Notes to the public in relation to any Notes in any Relevant
Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and
the Notes to be offered so as to enable an investor to decide to
purchase or subscribe for the Notes, as the same may be varied
in that Member State by any measure implementing the Prospectus
Directive in that Member State, the expression Prospectus
Directive means Directive 2003/71/EC (and amendments thereto,
including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member State), and includes any
relevant implementing measure in the Relevant Member State and
the expression 2010 PD Amending Directive means Directive
2010/73/EU.
Each underwriter has represented and agreed that:
|
|
|
|
(a)
|
it has only communicated or caused to be communicated and will
only communicate or cause to be communicated an invitation or
inducement to engage in investment activity (within the meaning
of Section 21 of the Financial Services and Markets Act
2000 (FSMA) received by it in connection with the
issue or sale of the Notes in circumstances in which
Section 21(1) of the FSMA does not apply to us; and
|
|
|
(b)
|
it has complied and will comply with all applicable provisions
of the FSMA with respect to anything done by it in relation to
the Notes in, from or otherwise involving the United Kingdom.
|
The Notes may not be offered or sold in Hong Kong by means of
any document other than (i) in circumstances which do not
constitute an offer to the public within the meaning of the
Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii) to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder, or (iii) in other
circumstances which do not result in this prospectus supplement
or the accompanying prospectus being a prospectus
within the meaning of the Companies Ordinance (Cap.32, Laws of
Hong Kong), and no advertisement, invitation or document
relating to the Notes may be issued or may be in the possession
of any person for the purpose of issue (in each case whether in
Hong Kong or elsewhere), which is directed at, or the contents
of which are likely to be accessed or read by, the public in
Hong Kong (except if permitted to do so under the laws of Hong
Kong) other than with respect to Notes which are or are intended
to be disposed of only to persons outside Hong Kong or only to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder.
The Notes have not been and will not be registered under the
Financial Instruments and Exchange Law of Japan (the
FIEL) and each underwriter has agreed that it will
not offer or sell any Notes, directly or indirectly, in Japan or
to, or for the benefit of, any resident of Japan (which term as
used herein means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan),
or to
S-21
others for reoffering or resale, directly or indirectly, in
Japan or to a resident of Japan, except pursuant to an exemption
from the registration requirements of, and otherwise in
compliance with, the FIEL and any other applicable laws,
regulations and ministerial guidelines of Japan.
Neither this prospectus supplement nor the accompanying
prospectus has been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, none of this prospectus
supplement, the accompanying prospectus and any other document
or material in connection with the offer or sale, or invitation
for subscription or purchase, of the Notes may be circulated or
distributed, nor may any Notes be offered or sold, or be made
the subject of an invitation for subscription or purchase,
whether directly or indirectly, to persons in Singapore other
than (i) to an institutional investor under
Section 274 of the Securities and Futures Act,
Chapter 289 of Singapore (the SFA),
(ii) to a relevant person pursuant to Section 275(1),
or any person pursuant to Section 275(1A), and in
accordance with the conditions specified in Section 275 of
the SFA or (iii) otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the
SFA, in each case subject to compliance with conditions set
forth in the SFA.
Where the Notes are subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor; or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary is an accredited investor,
shares, debentures and units of shares and debentures of that
corporation or the beneficiaries rights and interest in
that trust shall not be transferable for 6 months after
that corporation or that trust has acquired the Notes under
Section 275 except: (1) to an institutional investor
under Section 274 of the SFA or to a relevant person, or
any person pursuant to Section 275(1A), and in accordance
with the conditions, specified in Section 275 of the SFA;
(2) where no consideration is given for the transfer; or
(3) by operation of law.
S-22
VALIDITY
OF THE NOTES
The validity of the Notes offered hereby will be passed upon for
us by Davis Polk & Wardwell LLP, New York, New
York and for the underwriters by Debevoise & Plimpton
LLP, New York, New York. Debevoise & Plimpton LLP has
in the past provided, and continues to provide, legal services
to us.
EXPERTS
The consolidated financial statements and managements
assessment of the effectiveness of internal control over
financial reporting (which is included in Managements
Annual Report on Internal Control over Financial Reporting)
incorporated in this prospectus supplement and the accompanying
prospectus by reference to the Annual Report on
Form 10-K
for the year ended December 31, 2010, have been so
incorporated in reliance on the report of PricewaterhouseCoopers
LLP, an independent registered public accounting firm, given on
the authority of said firm as experts in auditing and accounting.
S-23
BENEFIT
PLAN INVESTOR CONSIDERATIONS
Each fiduciary of a pension, profit-sharing or other employee
benefit plan subject to the Employee Retirement Income Security
Act of 1974, as amended (ERISA), (a
Plan) should consider the fiduciary standards of
ERISA in the context of the Plans particular circumstances
before authorizing an investment in the Notes. Accordingly,
among other factors, the fiduciary should consider whether the
investment would satisfy the prudence and diversification
requirements of ERISA and would be consistent with the documents
and instruments governing the Plan.
In addition, CIGNA and certain of its affiliates, including
Connecticut General Life Insurance Company and Life Insurance of
North America, may each be considered a party in
interest within the meaning of ERISA, or a
disqualified person within the meaning of the Code,
with respect to many Plans, as well as many individual
retirement accounts and Keogh plans (also Plans).
ERISA Section 406 and Code Section 4975 generally
prohibit transactions between Plans and parties in interest or
disqualified persons. Prohibited transactions within the meaning
of ERISA or the Code would likely arise, for example, if the
Notes are acquired by or with the assets of a Plan with respect
to which CIGNA or any of its affiliates is a service provider or
other party in interest, unless the Notes are acquired pursuant
to an exemption from the prohibited transaction
rules. A violation of these prohibited transaction rules could
result in an excise tax or other liabilities under ERISA
and/or
Section 4975 of the Code for such persons, unless exemptive
relief is available under an applicable statutory or
administrative exemption.
Section 408(b)(17) of ERISA and Section 4975(d)(20) of
the Code, regarding transactions for adequate consideration with
parties in interest that are not fiduciaries (the
service-provider exemption), and five prohibited
transaction class exemptions (PTCEs) issued by the
U.S. Department of Labor may provide exemptive relief for
direct or indirect prohibited transactions resulting from the
purchase or holding of the Notes. Those class exemptions are
PTCE 96-23
(for certain transactions determined by in-house asset
managers),
PTCE 95-60
(for certain transactions involving insurance company general
accounts),
PTCE 91-38
(for certain transactions involving bank collective investment
funds),
PTCE 90-1
(for certain transactions involving insurance company separate
accounts), and
PTCE 84-14
(for certain transactions determined by independent qualified
asset managers). There can be no assurance that any of these
statutory or class exemptions will be available with respect to
transactions in the Notes.
Because CIGNA or its affiliates may be considered a party in
interest with respect to Plans, the Notes may not be purchased,
held or disposed of by any Plan, any entity whose underlying
assets include plan assets by reason of any
Plans investment in the entity (a Plan Asset
Entity) or any person investing plan assets of
any Plan, unless such purchase, holding or disposition is
eligible for exemptive relief. Any purchaser, including any
fiduciary purchasing on behalf of a Plan, transferee or holder
of the Notes will be deemed to have represented, in its
corporate and, as applicable, fiduciary capacity, by its
purchase and holding of the Notes that either (a) it is not
a Plan or a Plan Asset Entity and is not purchasing such Notes
on behalf of or with plan assets of any Plan or with
any assets of a governmental, church or
non-U.S. plan
that is subject to any federal, state, local or
non-U.S. law
that is substantially similar to the provisions of
Section 406 of ERISA or Section 4975 of the Code
(Similar Laws) or (b) its purchase, holding and
disposition of the Notes will not result in a nonexempt
prohibited transaction under Section 406 of ERISA,
Section 4975 of the Code or any Similar Laws.
Due to the complexity of these rules and the penalties that may
be imposed upon persons involved in non-exempt prohibited
transactions, it is particularly important that fiduciaries or
other persons considering purchasing the Notes on behalf of or
with plan assets of any Plan or plan subject to
Similar Laws consult with their counsel regarding the
availability of exemptive relief under the service-provider
exemption or PTCEs
96-23,
95-60,
91-38,
90-1 or
84-14 or
similar exemptions under Similar Laws. Purchasers of the Notes
have exclusive responsibility for ensuring that their purchase
and holding of the Notes do not violate the fiduciary or
prohibited transaction rules of ERISA, the Code or any Similar
Laws. The sale of any Notes to a Plan, Plan-Asset Entity or plan
subject to Similar Laws is in no respect a representation by
CIGNA or any of its affiliates or representatives that such an
investment meets all relevant legal requirements with respect to
investments by any such plan generally or any particular plan,
or that such investment is appropriate for such plans generally
or any particular plan.
S-24
PROSPECTUS
CIGNA Corporation
Debt Securities (Senior,
Subordinated, Junior Subordinated)
Common Stock
Preferred Stock
Warrants
Purchase Contracts
Units
CIGNA Corporation may offer and sell the securities listed above
from time to time in one or more classes or series and in
amounts, at prices and on terms that we may determine at the
time of the offering. We will provide the specific terms of the
securities in supplements to this prospectus. The debt
securities, preferred stock, warrants and purchase contracts may
be convertible into or exercisable or exchangeable for common or
preferred stock or other securities of the Company or debt or
equity securities of one or more other entities. You should read
this prospectus and any related prospectus supplement carefully
before you invest in our securities.
Our common stock is listed on the New York Stock Exchange under
the symbol CI.
We may offer and sell these securities to or through one or more
underwriters, dealers and agents, or directly to purchasers, on
a continuous or delayed basis.
You should carefully consider the risk factors included in
our periodic reports filed with the Securities and Exchange
Commission under the Securities Exchange Act of 1934, as
amended, before you invest in any of our securities.
Neither the Securities and Exchange Commission nor any state
securities regulator has approved or disapproved of these
securities, or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus is August 10, 2009.
You should not assume that the information in this prospectus,
any prospectus supplement, or any document incorporated by
reference, is truthful or complete at any date other than the
date mentioned on the cover page of those documents.
Unless otherwise mentioned or unless the context requires
otherwise, when used in this prospectus, the terms
CIGNA, we, our and
us refer to CIGNA Corporation and its consolidated
subsidiaries, and the term the Company refers to
CIGNA Corporation, not including its consolidated subsidiaries.
Unless the context otherwise requires, including
means including without limitation.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
12
|
|
|
|
|
14
|
|
|
|
|
15
|
|
|
|
|
18
|
|
|
|
|
18
|
|
|
|
|
18
|
|
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement on
Form S-3
that we filed with the Securities and Exchange Commission, which
we refer to as the SEC, using a shelf
registration process. Under this shelf registration process, we
may offer and sell any combination of the securities described
in this prospectus in one or more offerings. This prospectus
provides you with a general description of the securities we may
offer. Each time we use this prospectus to offer securities, we
will provide a prospectus supplement and, if applicable, a
pricing supplement. The prospectus supplement and any applicable
pricing supplement will describe the specific amounts, prices
and other material terms of the securities being offered at that
time. The prospectus supplement and any applicable pricing
supplement may also add, update or change the information in
this prospectus. You should read this prospectus, the applicable
prospectus supplement and any applicable pricing supplement,
together with the information contained in the documents
referred to under the heading Where You Can Find More
Information.
When acquiring any securities discussed in this prospectus, you
should rely only on the information contained or incorporated by
reference in this prospectus, any prospectus supplement and any
free writing prospectus that we authorize to be
delivered to you. Neither we, nor any underwriters or agents,
have authorized anyone to provide you with different
information. We are not offering the securities in any
jurisdiction in which an offer or solicitation is not authorized
or in which the person making such offer or solicitation is not
qualified to do so or to anyone to whom it is unlawful to make
an offer or solicitation.
2
SPECIAL
NOTE ON FORWARD-LOOKING STATEMENTS AND RISK
FACTORS
We have made forward-looking statements in this prospectus and
the documents incorporated by reference in this prospectus.
Forward-looking statements may contain information about
financial prospects, economic conditions, trends and other
uncertainties. These forward-looking statements are based on
managements beliefs and assumptions and on information
available to management at the time the statements are or were
made. Forward-looking statements include but are not limited to
the information concerning, possible or assumed future business
strategies, financing plans, competitive position, potential
growth opportunities, potential operating performance
improvements, trends, and in particular, CIGNAs
productivity initiatives, litigation and other legal matters,
operational improvement in the health care operations, and the
outlook for CIGNAs results. Forward-looking statements
include all statements that are not historical facts and can be
identified by the use of forward-looking terminology such as the
words believe, expect, plan,
intend, anticipate,
estimate, predict,
potential, may, should or
similar expressions.
You should not place undue reliance on these forward-looking
statements. CIGNA cautions that actual results could differ
materially from those that management expects, depending on the
outcome of certain factors. Some factors that could cause actual
results to differ materially from the forward-looking statements
include:
1. increased medical costs that are higher than anticipated
in establishing premium rates in the Companys health care
operations, including increased use and costs of medical
services;
2. increased medical, administrative, technology or other
costs resulting from new legislative and regulatory requirements
imposed on the Companys employee benefits businesses;
3. challenges and risks associated with implementing
operational improvement initiatives and strategic actions in the
ongoing operations of the businesses, including those related
to: (i) offering products that meet emerging market needs,
(ii) strengthening underwriting and pricing effectiveness,
(iii) strengthening medical cost and medical membership
results, (iv) delivering quality member and provider
service using effective technology solutions, (v) lowering
administrative costs, and (vi) transitioning to an
integrated operating company model, including operating
efficiencies related to the transition;
4. risks associated with pending and potential state and
federal class action lawsuits, disputes regarding reinsurance
arrangements, other litigation and regulatory actions
challenging the Companys businesses, government
investigations and proceedings, and tax audits and related
litigation;
5. heightened competition, particularly price competition,
which could reduce product margins and constrain growth in the
Companys businesses, primarily the health care business;
6. risks associated with the Companys mail order
pharmacy business which, among other things, includes any
potential operational deficiencies or service issues as well as
loss or suspension of state pharmacy licenses;
7. significant changes in interest rates and deterioration
in the loan to value ratios of commercial real estate
investments for a sustained period of time;
8. downgrades in the financial strength ratings of the
Companys insurance subsidiaries, which could, among other
things, adversely affect new sales, retention of current
business, as well as the downgrade in the financial strength
ratings of reinsurers which could result in increased statutory
reserve or capital requirements;
9. limitations on the ability of the Companys
insurance subsidiaries to dividend capital to the parent company
as a result of downgrades in the subsidiaries financial
strength ratings, changes in statutory reserve or capital
requirements or other financial constraints;
10. inability of the program adopted by the Company to
substantially reduce equity market risks for reinsurance
contracts that guarantee minimum death benefits under certain
variable annuities (including possible market difficulties in
entering into appropriate futures contracts and in matching such
contracts to the underlying equity risk);
3
11. adjustments to the reserve assumptions (including
lapse, partial surrender, mortality, interest rates and
volatility) used in estimating the Companys liabilities
for reinsurance contracts covering guaranteed minimum death
benefits under certain variable annuities;
12. adjustments to the assumptions (including annuity
election rates and amounts collectible from reinsurers) used in
estimating the Companys assets and liabilities for
reinsurance contracts covering guaranteed minimum income
benefits under certain variable annuities;
13. significant stock market declines, which could, among
other things, result in increased expenses for guaranteed
minimum income benefit contracts, guaranteed minimum death
benefit contracts and the Companys pension plans in future
periods as well as the recognition of additional pension
obligations;
14. unfavorable claims experience related to workers
compensation and personal accident exposures of the run-off
reinsurance business, including losses attributable to the
inability to recover claims from retrocessionaires;
15. significant deterioration in economic conditions and
significant market volatility, which could have an adverse
effect on the Companys operations, investments, liquidity
and access to capital markets;
16. significant deterioration in economic conditions and
significant market volatility, which could have an adverse
effect on the businesses of our customers (including the amount
and type of healthcare services provided to their workforce,
loss in workforce and our customers ability to pay
receivables) and our vendors (including their ability to provide
services);
17. changes in public policy and in the political
environment, which could affect state and federal law, including
legislative and regulatory proposals related to health care
issues, which could increase cost and affect the market for the
Companys health care products and services; and amendments
to income tax laws, which could affect the taxation of employer
provided benefits, and certain insurance products such as
corporate-owned life insurance;
18. potential public health epidemics and bio-terrorist
activity, which could, among other things, cause the
Companys covered medical and disability expenses, pharmacy
costs and mortality experience to rise significantly, and cause
operational disruption, depending on the severity of the event
and number of individuals affected;
19. risks associated with security or interruption of
information systems, which could, among other things, cause
operational disruption;
20. challenges and risks associated with the successful
management of the Companys outsourcing projects or key
vendors, including the agreement with IBM for provision of
technology infrastructure and related services;
21. the ability to successfully integrate and operate the
businesses acquired from Great-West by, among other things,
renewing insurance and administrative services contracts on
competitive terms, retaining and growing membership, realizing
revenue, expense and other synergies, successfully leveraging
the information technology platform of the acquired businesses,
and retaining key personnel; and
22. the ability of the Company to execute its growth plans
by successfully managing Great-West Healthcares
outsourcing projects and leveraging the Companys
capabilities and those of the business acquired from Great-West
to further enhance the combined organizations network
access position, underwriting effectiveness, delivery of quality
member and provider service, and increased penetration of its
membership base with differentiated product offerings.
This list of important factors is not intended to be exhaustive.
Other sections of CIGNAs most recent Annual Report on
Form 10-K,
including the Risk Factors section, our
Form 10-Q
for the quarter ended June 30, 2009 and other documents
filed with the Securities and Exchange Commission include both
expanded discussion of these factors and additional risk factors
and uncertainties that could preclude CIGNA from
4
realizing the forward-looking statements. CIGNA does not assume
any obligation to update any forward-looking statements, whether
as a result of new information, future events or otherwise,
except as required by law.
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements
and other information with the SEC under the Securities Exchange
Act of 1934. You may read and copy all or any portion of this
information at the SECs principal office in
Washington, D.C., and copies of all or any part thereof may
be obtained from the Public Reference Section of the SEC,
100 F Street, N.E., Washington, D.C. 20549 after
payment of fees prescribed by the SEC. Please call the SEC at
1-800-SEC-0330
for further information about the public reference room.
The SEC also maintains an Internet website that contains
reports, proxy statements and other information about issuers,
like CIGNA, who file electronically with the SEC. The address of
that site is www.sec.gov.
Our Internet website address is
www.cigna.com. This reference to our website is intended
to be an inactive textual reference only. Our website and the
information contained therein or connected thereto are not
incorporated by reference into this prospectus.
This prospectus is part of the registration statement and does
not contain all of the information included in the registration
statement. Whenever a reference is made in this prospectus to
any contract or other document of CIGNA, the reference may not
be complete and you should refer to the exhibits that are a part
of the registration statement for a copy of the contract or
document.
The SEC allows us to incorporate by reference
information into this prospectus, which means that we can
disclose important information to you by referring you to
another document filed separately with the SEC. The information
incorporated by reference is deemed to be part of this
prospectus, except for any information that is superseded by
subsequent incorporated documents or by information that is
contained directly in this prospectus or any prospectus
supplement. This prospectus incorporates by reference the
documents set forth below that CIGNA has previously filed with
the SEC and that are not delivered with this prospectus. These
documents contain important information about CIGNA and its
financial condition.
|
|
|
CIGNA SEC Filings (File No. 1-8323)
|
|
Period
|
|
Annual Report on
Form 10-K
Quarterly Reports on
Form 10-Q
|
|
Fiscal year ended December 31, 2008
Quarterly periods ended March 31, 2009 and June 30, 2009
|
Current Reports on
Form 8-K
|
|
Filed on January 5, 2009, May 12, 2009,
|
|
|
May 26, 2009, June 24, 2009 and July 6, 2009
|
All documents filed by us pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Securities Exchange Act of 1934
(excluding any information furnished under Items 2.02 or
7.01 in any Current Report on
Form 8-K)
between the date of this prospectus and the termination of the
offering of securities under this prospectus shall also be
deemed to be incorporated herein by reference. Any statement
contained in any document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified
or superseded for purposes of this prospectus to the extent that
a statement contained in this prospectus or in any other
subsequently filed document which also is or is deemed to be
incorporated by reference in this prospectus modifies or
supersedes such statement. Any statement so modified or
superseded shall not be deemed, except as so modified or
superseded, to constitute a part of this prospectus.
To obtain a copy of these filings at no cost, you may write or
telephone us at the following address:
CIGNA
Corporation
Two Liberty Place, 1601 Chestnut Street
Philadelphia, PA 19192
Attention: Investor Relations
(215) 761-1000
Exhibits to the filings will not be sent, however, unless those
exhibits have specifically been incorporated by reference into
such document.
5
CIGNA
CORPORATION
CIGNA Corporation had consolidated shareholders equity of
$3.6 billion and assets of $41.4 billion as of
December 31, 2008, and revenues of $19.1 billion for
the year then ended. CIGNA Corporation and its subsidiaries
constitute one of the largest investor-owned health service
organizations in the United States. Our subsidiaries are major
providers of health care and related benefits, the majority of
which are offered through the workplace, including health care
products and services; group disability, life and accident
insurance; and workers compensation case management and
related services. The Company also has certain inactive
businesses, including a run-off reinsurance operation.
CIGNAs major insurance subsidiary, Connecticut General
Life Insurance Company (CG Life), traces its origins
to 1865. CIGNA Corporation was incorporated in the State of
Delaware in 1981.
CIGNA Corporation is a holding company and is not an insurance
company. Its subsidiaries conduct various businesses, which are
described in our most recent Annual Report on
Form 10-K.
CIGNA Corporations principal executive offices are located
at Two Liberty Place, 1601 Chestnut Street, Philadelphia, PA
19192. Our telephone number is
(215) 761-1000.
For additional information concerning CIGNA, please see our most
recent Annual Report on Form
10-K and our
other filings with the SEC. See Where You Can Find More
Information.
USE OF
PROCEEDS
Unless we inform you otherwise in a prospectus supplement or
free writing prospectus, the net proceeds from the
sale of the securities will be added to CIGNAs general
funds and used for general corporate purposes, including the
repayment of indebtedness.
DESCRIPTION
OF DEBT SECURITIES
This prospectus describes certain general terms and provisions
of the debt securities. When we offer to sell a particular
series of debt securities, we will describe the specific terms
of the debt securities in a supplement to this prospectus. The
prospectus supplement will also indicate whether the general
terms and provisions described in this prospectus apply to a
particular series of debt securities.
The senior debt securities are to be issued under an indenture
(the Senior Indenture) entered into between CIGNA
Corporation and U.S. Bank National Association, as trustee.
The subordinated debt securities are to be issued under a
separate indenture (the Subordinated Indenture) also
between CIGNA Corporation and U.S. Bank National
Association, as trustee. The junior subordinated debt securities
are to be issued under a separate indenture (the Junior
Subordinated Indenture) also between CIGNA Corporation and
U.S. Bank National Association, as trustee. The Senior
Indenture, Subordinated Indenture and the Junior Subordinated
Indenture are sometimes referred to individually as an
Indenture or collectively as the
Indentures.
We sometimes refer below to specific sections of one or more of
the Indentures. When we do so, we indicate where you can find
the relevant section in the Indentures by noting the section
number in parentheses. When we do refer to specific sections
contained in the Indentures or terms defined in the Indentures,
including important terms, which we capitalize here, we use them
in this prospectus in the same way we use them in the
Indentures, and you should refer to the Indentures themselves
for detailed, specific, legal descriptions. In this section,
Description of Debt Securities, when we refer to
CIGNA, we refer to CIGNA Corporation, not including
its consolidated subsidiaries.
We have summarized some terms of the Indentures. The summary is
not complete. The Indentures were filed as exhibits to the
registration statement of which this prospectus is a part. You
should read the Indentures for a complete statement of the
provisions summarized in this prospectus and for provisions that
may be important to you. The Indentures are subject to and
governed by the Trust Indenture Act of 1939, as amended.
Ranking
The debt securities will be our direct, unsecured obligations.
The senior debt securities will rank equally with all of our
other senior and unsecured, unsubordinated debt. The
subordinated debt securities will have a
6
junior position to all of our senior debt. The junior
subordinated debt securities will have a junior position to all
subordinated debt securities.
Because a significant part of our operations are conducted
through subsidiaries, a significant portion of our cash flow,
and consequently, our ability to service debt, including the
debt securities, is dependent upon the earnings of our
subsidiaries and the transfer of funds by those subsidiaries to
us in the form of dividends or other transfers.
In addition, holders of the debt securities will have a junior
position to claims of creditors against our subsidiaries,
including policy holders, trade creditors, debtholders, secured
creditors, taxing authorities, guarantee holders and any
preferred shareholders, except to the extent that we are
recognized as a creditor of our subsidiary. Any claims of CIGNA
as the creditor of its subsidiary would be subordinate to any
security interest in the assets of such subsidiary and any
indebtedness of such subsidiary senior to that held by us.
In addition to general state law restrictions on payments of
dividends and other distributions to shareholders applicable to
all corporations, HMOs and insurance companies, including some
of CIGNAs direct and indirect subsidiaries, are subject to
further state regulations that, among other things, may require
those companies to maintain certain levels of equity, and
restrict the amount of dividends and other distributions that
may be paid to CIGNA.
Terms of
the Debt Securities to be Described in the Prospectus
Supplement
The Indentures do not limit the amount of debt securities that
we may issue under them. We may issue debt securities under the
Indentures up to an aggregate principal amount as we may
authorize from time to time. The prospectus supplement will
describe the terms of any debt securities being offered,
including:
|
|
|
|
|
whether the debt securities will be senior debt securities,
subordinated debt securities or junior subordinated debt
securities;
|
|
|
|
any limit on the aggregate principal amount of the debt
securities;
|
|
|
|
the date or dates on which the principal will be payable;
|
|
|
|
the interest rate, if any, and the method for calculating the
interest rate;
|
|
|
|
the interest payment dates and the record dates for interest
payments;
|
|
|
|
our right, if any, to defer payment of interest and the maximum
length of this deferral period;
|
|
|
|
any mandatory or optional redemption terms or prepayment or
sinking fund provisions;
|
|
|
|
the place where we will pay principal, interest and any premium;
|
|
|
|
the currency or currencies, if other than the currency of the
United States, in which principal, interest and any premium will
be paid;
|
|
|
|
if other than denominations of $2,000 or multiples of $1,000,
the denominations in which the debt securities will be issued;
|
|
|
|
whether the debt securities will be issued in the form of global
securities;
|
|
|
|
additional provisions, if any, relating to the discharge of our
obligations under the debt securities;
|
|
|
|
whether the amount of payment of principal (or premium, if any)
or interest, if any, will be determined with reference to one or
more indices;
|
|
|
|
the portion of the principal amount of the debt securities to be
paid upon acceleration of maturity thereof;
|
|
|
|
any authenticating or paying agents, registrars or other
agents; and
|
|
|
|
other specific terms, including any additional events of
default, covenants or warranties. (Section 301)
|
7
Events of
Default and Notice Thereof
When we use the term Event of Default with respect
to debt securities of any series we mean:
|
|
|
|
|
we fail to pay principal (including any sinking fund payment)
of, or premium (if any) on, any debt security of that series
when due;
|
|
|
|
we fail to pay interest, if any, on any debt security of that
series when due and the failure continues for a period of
30 days;
|
|
|
|
in the case of senior debt securities or subordinated debt
securities, we fail to perform in any material respect any
covenant in an Indenture not specified in the previous two
bullet points (other than a covenant included in an Indenture
solely for the benefit of a different series of debt securities)
and the failure to perform continues for a period of
90 days after receipt of a specified written notice to
us; and
|
|
|
|
certain events of bankruptcy, insolvency, reorganization,
receivership or liquidation of CIGNA. (Section 501)
|
An Event of Default with respect to debt securities of a
particular series may not constitute an Event of Default with
respect to debt securities of any other series of debt
securities.
If an Event of Default under an Indenture occurs with respect to
the debt securities of any series and is continuing, then the
Trustee or the holders of at least 25% in principal amount of
the Outstanding Securities of that series may require us to
repay immediately the entire principal amount (or, if the debt
securities of that series are Original Issue Discount
Securities, such portion of the principal amount as may be
specified in the terms of that series) of all Outstanding
Securities of that series; provided, however, that under certain
circumstances the holders of a majority in aggregate principal
amount of Outstanding Securities of that series may rescind or
annul such acceleration and its consequences. (Section 502)
Each of the Indentures contains a provision entitling the
Trustee, subject to the duty of the Trustee during a default to
act with the required standard of care (Section 601), to be
indemnified by the holders of debt securities before proceeding
to exercise any right or power under that Indenture at the
request of such holders. (Section 603) Subject to
these provisions in the Indentures for the indemnification of
the Trustee and certain other limitations, the holders of a
majority in aggregate principal amount of the debt securities of
each affected series then Outstanding may direct the time,
method and place of conducting any proceeding for any remedy
available to the Trustee or exercising any trust or power
conferred on the Trustee. (Sections 512 and 513)
Each of the Indentures provides that the Trustee may withhold
notice to the holders of the debt securities of any default
(except in payment of principal (or premium, if any) or
interest, if any) if the Trustee considers it in the interest of
the holders of the debt securities to do so. (Section 602)
Each of the Indentures provides that holders of at least 25% in
aggregate principal amount of the Outstanding Securities of any
series may seek to institute a proceeding with respect to the
Indentures or for any remedy thereunder only after:
|
|
|
|
|
such holders have made a written request to the Trustee,
|
|
|
|
such holders have offered an indemnity reasonably satisfactory
to the Trustee to institute a proceeding, and
|
|
|
|
the Trustee shall not have received from the holders of a
majority in aggregate principal amount of the Outstanding
Securities of that series a direction inconsistent with such
request and shall have failed to institute such proceeding
within 60 days. (Section 507)
|
These limitations do not apply, however, to a suit instituted by
a Holder of a debt security for enforcement of payment of the
principal of (or premium, if any) or interest, if any, on or
after the respective due dates expressed in such debt security.
(Section 508)
Each of the Indentures contains a covenant under which we are
required to furnish to the Trustee an annual statement as to the
compliance with all conditions and covenants of the Indentures.
(Section 1007)
8
Modification
and Waiver
Each of the Indentures (Section 901) provides that we,
together with the Trustee, may enter into supplemental
indentures without the consent of the holders of debt securities
to:
|
|
|
|
|
evidence the assumption by another person of our obligations;
|
|
|
|
add covenants for the benefit of the holders of all or any
series of debt securities;
|
|
|
|
add any additional Events of Default;
|
|
|
|
add or change an Indenture to permit or facilitate the issuance
of debt securities in bearer form;
|
|
|
|
add to, change or eliminate a provision of an Indenture if such
addition, change or elimination does not apply to a debt
security created prior to the execution of such supplemental
indenture or modify the rights of a Holder of any debt security
with respect to such provision;
|
|
|
|
secure any debt security;
|
|
|
|
establish the form or terms of debt securities of any series;
|
|
|
|
evidence the acceptance of appointment by a successor Trustee;
|
|
|
|
add to any provision of an Indenture to the extent necessary to
permit defeasance and discharge of any series of debt securities
if such action does not adversely affect the interests of the
holders of debt securities in any material respect;
|
|
|
|
cure any ambiguity or correct any inconsistency in an Indenture
or make other changes, provided that any such action does not
adversely affect the interests of the holders of debt securities
of any affected series in any material respect; or
|
|
|
|
conform an Indenture to any mandatory provision of law.
|
Other amendments and modifications of an Indenture may be made
with the consent of the holders of not less than a majority of
the aggregate principal amount of each series of the Outstanding
Securities affected by the amendment or modification. However,
no modification or amendment may, without the consent of the
Holder of each Outstanding Security affected:
|
|
|
|
|
change the stated maturity of the principal of (or premium, if
any) or any installment of principal or interest, if any, on any
such debt security;
|
|
|
|
reduce the principal amount of (or premium, if any) or the
interest rate, if any, on any such debt security or the
principal amount due upon acceleration of an Original Issue
Discount Security;
|
|
|
|
change the place or currency of payment of principal of (or
premium if any) or the interest, if any, on any such debt
security;
|
|
|
|
impair the right to institute suit for the enforcement of any
such payment on or with respect to any such debt security;
|
|
|
|
reduce the percentage of holders of debt securities necessary to
modify or amend an Indenture;
|
|
|
|
in the case of the Subordinated Indenture and Junior
Subordinated Indenture, modify the subordination provisions in a
manner adverse to the holders of the subordinated debt
securities and junior subordinated debt securities
respectively; or
|
|
|
|
modify the foregoing requirements or reduce the percentage of
Outstanding Securities necessary to waive compliance with
certain provisions of an Indenture or for waiver of certain
defaults. (Section 902)
|
The holders of at least a majority of the aggregate principal
amount of the Outstanding Securities of any series may, on
behalf of all holders of that series, waive our required
compliance with certain restrictive provisions of an Indenture
and may waive any past default under an Indenture, except a
default in the payment of principal, premium or interest or in
the performance of certain covenants. (Section 513)
9
Limitations
on Liens on Common Stock of Designated Subsidiaries
Each of the Indentures provides that so long as any of the debt
securities issued under that Indenture remains outstanding, we
will not, and we will not permit any of our Designated
Subsidiaries to, issue, assume, incur or guarantee any
indebtedness for borrowed money secured by a mortgage, pledge,
lien or other encumbrance, directly or indirectly, on any of the
common stock of a Designated Subsidiary owned by us or by any of
our Designated Subsidiaries, unless our obligations under the
debt securities and, if we so elect, any other of our
indebtedness ranking on a parity with, or prior to, the debt
securities, shall be secured equally and ratably with, or prior
to, such secured indebtedness for borrowed money so long as it
is outstanding and is so secured. (Section 1005)
Designated Subsidiary means Connecticut
General Life Insurance Company and Life Insurance Company of
North America, so long as it remains a Subsidiary, or any
Subsidiary which is a successor of such Designated Subsidiary.
(Section 101)
Consolidation,
Merger and Sale of Assets
We may not consolidate with or merge with or into any other
person (other than in a merger or consolidation in which we are
the surviving person) or sell our property and assets as, or
substantially as, an entirety to any person unless:
|
|
|
|
|
the person formed by the consolidation or with or into which we
are merged or the person that purchases our properties and
assets as, or substantially as, an entirety is a corporation,
partnership or trust organized and validly existing under the
laws of the United States of America, any State or the District
of Columbia, and any such successor or purchaser expressly
assumes CIGNAs obligations on the debt securities under a
supplemental indenture satisfactory to the Trustee;
|
|
|
|
immediately after giving effect to the transaction no Event of
Default shall have occurred and be continuing; and
|
|
|
|
a specified officers certificate and opinion of counsel
are delivered to the Trustee. (Section 801)
|
Upon compliance with the foregoing provisions, the successor or
purchaser will succeed to, and be substituted for CIGNA under
the Indentures with the same effect as if such successor or
purchaser had been the original obligor under the debt
securities, and thereafter CIGNA will be relieved of all
obligations and covenants under the Indentures and the debt
securities. (Section 802)
Defeasance
and Covenant Defeasance
If we deposit, in trust, with the Trustee (or other qualifying
trustee), sufficient cash or specified government obligations to
pay the principal of (and premium, if any) and interest and any
other sums due on the scheduled due date for the debt securities
of a particular series, then at our option and subject to
certain conditions (including the absence of an Event of
Default):
|
|
|
|
|
we will be discharged from our obligations with respect to the
debt securities of such series (which we refer to in this
prospectus as a legal defeasance), or
|
|
|
|
we will no longer be under any obligation to comply with the
covenants described above under Limitations on Liens on
Common Stock of Designated Subsidiaries and
Consolidation, Merger and Sale of Assets, an Event
of Default relating to any failure to comply with such covenants
will no longer apply to us, and, for subordinated debt
securities, the subordination provisions will no longer apply to
us (which we refer to in this prospectus as a covenant
defeasance).
|
If we exercise our legal defeasance option, payment of such debt
securities may not be accelerated because of an Event of
Default. If we exercise our covenant defeasance option, payment
of such debt securities may not be accelerated by reference to
the covenants from which we have been released or pursuant to
Events of Default referred to above which are no longer
applicable. If we fail to comply with our remaining obligations
with respect to such debt securities under an Indenture after we
exercise the covenant defeasance option and such debt securities
are declared due and payable because of the occurrence of any
Event of Default, the amount of money and government obligations
on deposit with the Trustee may be insufficient to
10
pay amounts due on the debt securities of such series at the
time of the acceleration resulting from such Event of Default.
However, we will remain liable for such payments.
(Section 1006)
Under current United States federal income tax laws, a legal
defeasance would be treated as an exchange of the relevant debt
securities in which holders of those debt securities might
recognize gain or loss. Unless accompanied by other changes in
the terms of the debt securities, a covenant defeasance
generally should not be treated as a taxable exchange. In order
to exercise our defeasance options, we must deliver to the
Trustee an opinion of counsel to the effect that the deposit and
related defeasance would not cause the holders of the debt
securities to recognize income, gain or loss for Federal income
tax purposes.
Subordination
of Subordinated and Junior Subordinated Debt
Securities
Unless otherwise indicated in the prospectus supplement, the
following provisions will apply to the subordinated and junior
subordinated debt securities.
The subordinated debt securities and junior subordinated debt
securities will, to the extent set forth in the Subordinated
Indenture and Junior Subordinated Indenture respectively, be
subordinate in right of payment to the prior payment in full of
all Senior Debt (as defined below) of CIGNA, including the
senior debt securities. Upon any payment or distribution of
assets to creditors upon any liquidation, dissolution, winding
up, reorganization, assignment for the benefit of creditors,
marshaling of assets or any bankruptcy, insolvency, debt
restructuring or similar proceedings in connection with any
insolvency or bankruptcy proceeding of CIGNA, the holders of
Senior Debt of CIGNA will first be entitled to receive payment
in full of principal of (and premium, if any) and interest, if
any, on such Senior Debt of CIGNA before the holders of the
subordinated debt securities or junior subordinated securities,
as the case may be, will be entitled to receive or retain any
payment in respect of the principal of (and premium, if any) or
interest, if any, on the subordinated debt securities or junior
subordinated securities, as the case may be. (Subordinated
Indenture and Junior Subordinated Indenture
Section 1301-02)
If the maturity of any subordinated debt securities or junior
subordinated debt securities is accelerated, the holders of all
Senior Debt of CIGNA outstanding at the time of such
acceleration will first be entitled to receive payment in full
of all amounts due thereon before the holders of subordinated
debt securities or junior subordinated debt securities will be
entitled to receive any payment upon the principal of (or
premium, if any) or interest, if any, on the subordinated debt
securities or junior subordinated debt securities, as the case
may be. (Subordinated Indenture and Junior Subordinated
Indenture Section 1303)
No payments on account of principal (or premium, if any) or
interest, if any, in respect of the subordinated debt securities
or junior subordinated debt securities may be made if there
shall have occurred and be continuing.
|
|
|
|
|
a default in the payment of principal of (or premium, if any) or
interest on Senior Debt of CIGNA, or
|
|
|
|
an event of default with respect to any Senior Debt of CIGNA
resulting in the acceleration of the maturity thereof, or if any
judicial proceeding shall be pending with respect to any such
default. (Subordinated Indenture and Junior Subordinated
Indenture Section 1303)
|
Debt means (without duplication and without
regard to any portion of principal amount that has not accrued
and to any interest component thereof (whether accrued or
imputed) that is not due and payable) with respect to any
person, whether recourse is to all or a portion of the assets of
such person and whether or not contingent:
|
|
|
|
|
every obligation of such person for money borrowed;
|
|
|
|
every obligation of such person evidenced by bonds, debentures,
notes or other similar instruments;
|
|
|
|
every reimbursement obligation of such person with respect to
letters of credit, bankers acceptances or similar
facilities issued for the account of such person;
|
|
|
|
every obligation of such person issued or assumed as the
deferred purchase price of property or services (but excluding
trade accounts payable or accrued liabilities arising in the
ordinary course of business);
|
|
|
|
every capital lease obligation of such person; and
|
11
|
|
|
|
|
every obligation of the type referred to in the previous five
bullets of another person and all dividends of another person
the payment of which, in either case, such person has guaranteed
or is responsible or liable for, directly or indirectly, as
obligor or otherwise. (Subordinated Indenture and Junior
Subordinated Indenture Section 101)
|
With respect to either the subordinated debt securities or the
junior subordinated debt securities, Senior Debt
means with respect to any person the principal of (and premium,
if any) and interest, if any (including interest accruing on or
after the filing of any petition in bankruptcy or for
reorganization relating to such person to the extent that such
claim for post-petition interest is allowed in such proceeding),
on Debt of such person, whether incurred on or prior to the date
of the Subordinated Indenture or Junior Subordinated Indenture,
as the case may be, or thereafter incurred, unless, in the
instrument creating or evidencing the same or pursuant to which
the same is outstanding, it is provided that such obligations
are not superior in right of payment to the subordinated debt
securities or to the junior subordinated debt securities, as the
case may be, or to other Debt of such person which is pari passu
with, or subordinated to, the subordinated debt securities or
the junior subordinated debt securities, as the case may be;
provided, however, that Senior Debt with respect to the
subordinated debt securities does not include the subordinated
debt securities or junior subordinated debt securities; and
provided further that Senior Debt with respect to the junior
subordinated debt securities does not include the junior
subordinated debt securities. (Subordinated Indenture and Junior
Subordinated Indenture Section 101)
The Subordinated Indenture and Junior Subordinated Indenture do
not limit or prohibit the incurrence of additional Senior Debt
of CIGNA, which may include indebtedness that is senior to the
subordinated and junior subordinated debt securities, but
subordinate to other obligations of CIGNA. The senior debt
securities, when issued, will constitute Senior Debt of CIGNA.
At June 30, 2009, the Company had $2.3 billion of
Senior Debt, with respect to the subordinated debt securities,
outstanding and no subordinated or junior subordinated debt
securities outstanding.
The prospectus supplement may further describe the provisions,
if any, applicable to the subordination of the subordinated and
junior subordinated debt securities of a particular series.
Concerning
our Relationship with the Trustee
U.S. Bank National Association, will act as Trustee under
our Senior Indenture, Subordinated Indenture and our Junior
Subordinated Indenture. We maintain customary banking
relationships in the ordinary course of business with the
Trustee and its affiliates.
Governing
Law
Each of the Indentures is governed by and shall be construed in
accordance with the internal laws of the State of New York.
FORM OF
DEBT SECURITIES
Each debt security will be represented either by a certificate
issued in definitive form to a particular investor or by one or
more global securities representing the entire issuance of
securities. Certificated securities in definitive form and
global securities will be issued in registered form. Definitive
securities name you or your nominee as the owner of the
security, and in order to transfer or exchange these securities
or to receive payments other than interest or other interim
payments, you or your nominee must physically deliver the
securities to the Trustee. Global securities name a depositary
or its nominee as the owner of the debt securities represented
by these global securities.
We may issue the debt securities in the form of one or more
fully registered global securities that will be deposited with a
depositary or its nominee identified in the applicable
prospectus supplement and registered in the name of that
depositary or nominee. In those cases, one or more global
securities will be issued in a denomination or aggregate
denominations equal to the portion of the aggregate principal or
face amount of the securities to be represented by global
securities. Unless and until it is exchanged in whole for
securities in definitive registered form, a global security may
not be transferred except as a whole by and among the
12
depositary for the global security, the nominees of the
depositary or any successors of the depositary or those nominees.
If not described below, any specific terms of the depositary
arrangement with respect to any securities to be represented by
a global security will be described in the prospectus supplement
relating to those securities. (Sections 204 and
305) We anticipate that the following provisions will apply
to all depositary arrangements.
Ownership of beneficial interests in a global security will be
limited to persons, called participants, that have accounts with
the depositary. Upon the issuance of a global security, the
depositary will credit, on its book-entry registration and
transfer system, the participants accounts with the
respective principal or face amounts of the securities
beneficially owned by the participants. Any dealers,
underwriters or agents participating in the distribution of the
securities will designate the accounts to be credited. Ownership
of beneficial interests in a global security will be shown on,
and the transfer of ownership interests will be effected only
through, records maintained by the depositary, with respect to
interests of participants, and on the records of participants,
with respect to interests of persons holding through
participants. The laws of some states may require that some
purchasers of securities take physical delivery of these
securities in definitive form. These laws may impair your
ability to own, transfer or pledge beneficial interests in
global securities.
So long as the depositary, or its nominee, is the registered
owner of a global security, that depositary or its nominee, as
the case may be, will be considered the sole owner or holder of
the securities represented by the global security for all
purposes under the applicable Indenture. Except as described
below, owners of beneficial interests in a global security will
not be entitled to have the securities represented by the global
security registered in their names, will not receive or be
entitled to receive physical delivery of the securities in
definitive form and will not be considered the owners or holders
of the securities under the applicable Indenture. Accordingly,
each person owning a beneficial interest in a global security
must rely on the procedures of the depositary for that global
security and, if that person is not a participant, on the
procedures of the participant through which the person owns its
interest, to exercise any rights of a holder under the
applicable Indenture. We understand that under existing industry
practices, if we request any action of holders or if an owner of
a beneficial interest in a global security desires to give or
take any action that a holder is entitled to give or take under
the applicable Indenture, the depositary for the global security
would authorize the participants holding the relevant beneficial
interests to give or take that action, and the participants
would authorize beneficial owners owning through them to give or
take that action or would otherwise act upon the instructions of
beneficial owners holding through them.
Principal (or premium, if any) and interest payments on debt
securities represented by a global security registered in the
name of a depositary or its nominee will be made to the
depositary or its nominee, as the case may be, as the registered
owner of the global security. Neither CIGNA nor the Trustee nor
any agent of CIGNA or the Trustee will have any responsibility
or liability for any aspect of the records relating to payments
made on account of beneficial ownership interests in the global
security or for maintaining, supervising or reviewing any
records relating to those beneficial ownership interests.
We expect that the depositary for any of the securities
represented by a global security, upon receipt of any payment of
principal, premium, interest or other distribution of underlying
securities or other property to holders of that global security,
will immediately credit participants accounts in amounts
proportionate to their respective beneficial interests in that
global security as shown on the records of the depositary. We
also expect that payments by participants to owners of
beneficial interests in a global security held through
participants will be governed by standing customer instructions
and customary practices, as is now the case with securities held
for the accounts of customers in bearer form or registered in
street name, and will be the responsibility of those
participants.
If the depositary for any of these securities represented by a
global security is at any time unwilling or unable to continue
as depositary or ceases to be a clearing agency registered under
the Securities Exchange Act of 1934, and a successor depositary
registered as a clearing agency under the Securities Exchange
Act of 1934 is not appointed by us within 90 days, we will
issue securities in definitive form in exchange for the global
security that had been held by the depositary. In addition, we
may at any time and in our sole discretion decide not to have
any of the securities represented by one or more global
securities. If we make that decision, we will issue securities
in definitive form in exchange for all of the global security or
securities
13
representing those securities. Any securities issued in
definitive form in exchange for a global security will be
registered in the name or names that the depositary gives to the
Trustee or relevant agent of ours or theirs. It is expected that
the depositarys instructions will be based upon directions
received by the depositary from participants with respect to
ownership of beneficial interests in the global security that
had been held by the depositary.
DESCRIPTION
OF CAPITAL STOCK
Description
of Common Stock
The Company is authorized to issue 600,000,000 shares of
common stock, par value $0.25 per share, of which
272,704,706 shares were issued and outstanding at
July 17, 2009.
Holders of common stock are entitled to receive such dividends
as the board of directors of the Company may from time to time
declare. Payment of dividends on the common stock will at all
times be subject to, among other things, prior satisfaction of
dividend and sinking fund requirements, if any, of any series of
preferred stock that may then be outstanding, and the
availability of funds to the Company, which in turn may be
subject to fixed payment obligations which the Company may incur
in the future, and the ability of the Companys insurance
subsidiaries to declare and pay dividends under applicable
insurance regulatory requirements. No shares of preferred stock
are outstanding as of the date of this prospectus.
The Companys board of directors is divided into three
classes, each elected for a term of three years. Directors may
be removed only for cause. Holders of common stock have one vote
per share and have no cumulative voting rights. Subject to the
rights of creditors and the liquidation preferences of holders
of preferred stock, the holders of common stock are entitled to
share ratably in the remaining assets of the Company in the
event of its voluntary or involuntary liquidation or
dissolution. Holders of common stock have no preemptive rights.
All shares of common stock presently outstanding are, and all
such shares to be issued pursuant to this prospectus will be,
fully paid and nonassessable.
A majority vote of the outstanding common stock and any
preferred stock entitled to vote, generally voting together as a
single class, is required for the Companys shareholders to
amend, repeal or adopt any charter provision or bylaw provision,
except as related to the number, qualifications, election and
term of office of the Directors, where 80% vote of the
outstanding capital stock of the Company is required. Such
provisions could inhibit a change of control in situations that
the board of directors determines are not adequate or in the
best interests of shareholders, or that do not meet specified
fair price criteria and procedural conditions. In some
circumstances, some or all shareholders could be denied the
opportunity to realize a premium over the then-prevailing market
price for the shares.
Description
of Preferred Stock
The Companys Restated Certificate of Incorporation
authorizes the issuance of 25,000,000 shares of preferred
stock, par value $1.00 per share. No shares of preferred stock
are outstanding as of the date of this prospectus-The
Companys preferred stock may be issued from time to time
in one or more series, without shareholder approval, when
authorized by the board of directors. Subject to limitations
prescribed by law, the board of directors is authorized to
determine the voting powers (if any), designation, preferences
and relative, participating, optional or other special rights,
and qualifications, limitations or restrictions thereof, for
each series of preferred stock that may be issued, and to fix
the number of shares of each such series.
Section 203
of the Delaware General Corporation Law
Section 203 of the Delaware General Corporation Law
prohibits a defined set of transactions between a Delaware
corporation, such as us, and an interested stockholder. An
interested stockholder is defined as a person who, together with
any affiliates or associates of such person, beneficially owns,
directly or indirectly, 15% or more of the outstanding voting
shares of a Delaware corporation. This provision may prohibit
business combinations between an interested stockholder and a
corporation for a period of three years after the date the
interested stockholder becomes an interested stockholder. The
term business combination is broadly defined to include mergers,
consolidations, sales or other dispositions of assets having a
total value in excess of 10% of
14
the consolidated assets of the corporation, and some other
transactions that would increase the interested
stockholders proportionate share ownership in the
corporation.
This prohibition is effective unless:
|
|
|
|
|
the business combination is approved by the corporations
board of directors prior to the time the interested stockholder
becomes an interested stockholder;
|
|
|
|
the interested stockholder acquired at least 85% of the voting
stock of the corporation, other than stock held by directors who
are also officers or by qualified employee stock plans, in the
transaction in which it becomes an interested
stockholder; or
|
|
|
|
the business combination is approved by a majority of the board
of directors and by the affirmative vote of two-thirds of the
outstanding voting stock that is not owned by the interested
stockholder.
|
In general, the prohibitions do not apply to business
combinations with persons who were shareholders before we became
subject to Section 203.
Special
By-Laws Provisions
Our by-laws divide our board of directors into three classes of
directors serving staggered, three-year terms. Vacancies, and
newly-created directorships resulting from any increase in the
size of our board, may be filled by our board, even if the
directors then on the board do not constitute a quorum or only
one director is left in office. These provisions, together with
the provisions of Section 203 of the Delaware General
Corporation Law, could have the effect of delaying, deferring or
preventing a change in control or the removal of existing
management, of deterring potential acquirors from making an
offer to our shareholders and of limiting any opportunity to
realize premiums over prevailing market prices for our common
stock in connection therewith. This could be the case
notwithstanding that a majority of our shareholders might
benefit from such a change in control or offer.
Transfer
Agent and Registrar
Mellon Investor Services serves as the registrar and transfer
agent for the common stock.
Stock
Exchange Listing
Our common stock is listed on the New York Stock Exchange under
the trading symbol CI.
PLAN OF
DISTRIBUTION
General
Any of the securities being offered hereby and any accompanying
prospectus supplement may be sold in any one or more of the
following ways from time to time.
|
|
|
|
|
directly to purchasers;
|
|
|
|
through agents;
|
|
|
|
to or through underwriters;
|
|
|
|
through dealers;
|
|
|
|
directly to our shareholders; or
|
|
|
|
through a combination of any such methods of sale.
|
We may also issue the securities as a dividend or distribution
to our shareholders.
In addition, we may enter into derivative transactions with
third parties, or sell securities not covered by this prospectus
to third parties in privately negotiated transactions. If the
applicable prospectus supplement indicates, in connection with
such a transaction, the third parties may, pursuant to this
prospectus and the applicable prospectus supplement, sell
securities covered by this prospectus and the applicable
prospectus supplement. If so, the third party may use securities
borrowed from us or others to settle such sales and may use
securities received from us to close out any related short
positions. We may also loan or pledge securities covered by this
prospectus and the applicable prospectus supplement to third
parties, who may sell the loaned
15
securities or, in an event of default in the case of a pledge,
sell the pledged securities pursuant to this prospectus and the
applicable prospectus supplement.
The distribution of the securities may be effected from time to
time in one or more transactions at a fixed price or prices,
which may be changed, at market prices prevailing at the time of
sale, at prices related to such prevailing market prices or at
negotiated prices.
We may solicit offers to purchase directly. Offers to purchase
securities also may be solicited by agents designated by us from
time to time. Any such agent involved in the offer or sale of
the securities in respect of which this prospectus is delivered
will be named, and any commissions payable by us to such agent
will be set forth, in the applicable prospectus supplement.
Unless otherwise indicated in such prospectus supplement, any
such agent will be acting on a reasonable best efforts basis for
the period of its appointment. Any such agent may be deemed to
be an underwriter, as that term is defined in the Securities Act
of 1933, of the securities so offered and sold.
If securities are sold by means of an underwritten offering, we
will execute an underwriting agreement with an underwriter or
underwriters at the time an agreement for such sale is reached,
and the names of the specific managing underwriter or
underwriters, as well as any other underwriters, the respective
amounts underwritten and the terms of the transaction, including
commissions, discounts and any other compensation of the
underwriters and dealers, if any, will be set forth in the
applicable prospectus supplement which will be used by the
underwriters to make resales of the securities in respect of
which this prospectus is being delivered to the public. If
underwriters are utilized in the sale of any securities in
respect of which this prospectus is being delivered, such
securities will be acquired by the underwriters for their own
account and may be resold from time to time in one or more
transactions, including negotiated transactions, at fixed public
offering prices or at varying prices determined by the
underwriters at the time of sale. Securities may be offered to
the public either through underwriting syndicates represented by
managing underwriters or directly by one or more underwriters.
If any underwriter or underwriters are utilized in the sale of
securities, unless otherwise indicated in the applicable
prospectus supplement, the underwriting agreement will provide
that the obligations of the underwriters are subject to certain
conditions precedent and that the underwriters with respect to a
sale of such securities will be obligated to purchase all such
securities if any are purchased.
We may grant to the underwriters options to purchase additional
securities, to cover over-allotments, if any, at the initial
public offering price (with additional underwriting commissions
or discounts), as may be set forth in the prospectus supplement
relating thereto. If we grant any over-allotment option, the
terms of such over-allotment option will be set forth in the
prospectus supplement for such securities.
If a dealer is used in the sale of the securities in respect of
which this prospectus is delivered, we will sell such securities
to the dealer, as principal. The dealer may then resell such
securities to the public at varying prices to be determined by
such dealer at the time of resale. Any such dealer may be deemed
to be an underwriter, as such term is defined in the Securities
Act, of the securities so offered and sold. The name of the
dealer and their terms of the transaction will be set forth in
the prospectus supplement relating thereto.
Offers to purchase securities may be solicited directly by us
and the sale thereof may be made by us directly to institutional
investors or others, who may be deemed to be underwriters within
the meaning of the Securities Act of 1933 with respect to any
resale thereof. We may also offer securities through agents in
connection with a distribution to our shareholders of rights to
purchase such securities. The terms of any such sales will be
described in the prospectus supplement relating thereto.
We may offer our equity securities into an existing trading
market on the terms described in the applicable prospectus
supplement. Underwriters and dealers who may participate in any
at-the-market
offerings will be described in the prospectus supplement
relating thereto.
Pursuant to any standby underwriting agreement entered into in
connection with a subscription rights offering to our
shareholders, persons acting as standby underwriters may receive
a commitment fee for all securities underlying the subscription
rights that the underwriter commits to purchase on a standby
basis. Additionally, prior to the expiration date with respect
to any subscription rights, any standby underwriters in a
subscription rights offering to our shareholders may offer such
securities on a when-issued basis, including securities to be
acquired through the purchase and exercise of subscription
rights, at prices set from time to
16
time by the standby underwriters. After the expiration date with
respect to such subscription rights, the underwriters may offer
securities of the type underlying the subscription rights,
whether acquired pursuant to a standby underwriting agreement,
the exercise of the subscription rights or the purchase of such
securities in the market, to the public at a price or prices to
be determined by the underwriters. The standby underwriters may
thus realize profits or losses independent of the underwriting
discounts or commissions paid by us. If we do not enter into a
standby underwriting arrangement in connection with a
subscription rights offering to our shareholders, we may elect
to retain a dealer-manager to manage such a subscription rights
offering for us. Any such dealer-manager may offer securities of
the type underlying the subscription rights acquired or to be
acquired pursuant to the purchase and exercise of subscription
rights and may thus realize profits or losses independent of any
dealer-manager fee paid by us.
Securities may also be offered and sold, if so indicated in the
applicable prospectus supplement, in connection with a
remarketing upon their purchase, in accordance with a redemption
or repayment pursuant to their terms, or otherwise, by one or
more firms (remarketing firms) acting as principals
for their own accounts or as agents for us. Any remarketing firm
will be identified and the terms of its agreement, if any, with
us and its compensation will be described in the applicable
prospectus supplement. Remarketing firms may be deemed to be
underwriters, as that term is defined in the Securities Act of
1933, in connection with the securities remarketed thereby.
If so indicated in the applicable prospectus supplement, we may
authorize agents, dealers or underwriters to solicit offers by
certain institutions to purchase securities from us at the
public offering price set forth in the applicable prospectus
supplement pursuant to delayed delivery contracts providing for
payment and delivery on the date or dates stated in the
applicable prospectus supplement. Such delayed delivery
contracts will be subject to only those conditions set forth in
the applicable prospectus supplement. A commission indicated in
the applicable prospectus supplement will be paid to
underwriters and agents soliciting purchases of securities
pursuant to delayed delivery contracts accepted by us.
Agents, underwriters, dealers and remarketing firms may be
entitled under relevant agreements with us to indemnification by
us against certain liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments
which such agents, underwriters, dealers and remarketing firms
may be required to make in respect thereof.
Any underwriter may engage in stabilizing and syndicate covering
transactions in accordance with Rule 104 under
Regulation M. Rule 104 permits stabilizing bids to
purchase the underlying security so long as the stabilizing bids
do not exceed a specified maximum. The underwriters may
over-allot shares of the securities in connection with an
offering of securities, thereby creating a short position in the
underwriters account. Syndicate covering transactions
involve purchases of the securities in the open market after the
distribution has been completed in order to cover syndicate
short positions. Stabilizing and syndicate covering transactions
may cause the price of the securities to be higher than it would
otherwise be in the absence of such transactions. These
transactions, if commenced, may be discontinued at any time.
Unless otherwise specified in the applicable prospectus
supplement, each series of securities, other than our common
stock that is listed on the New York Stock Exchange, will be a
new issue and will have no established trading market. We may
elect to list any series of securities on an exchange but,
unless otherwise specified in the applicable prospectus
supplement, we shall not be obligated to do so. In addition,
underwriters will not be obligated to make a market in any
securities. No assurance can be given as to the liquidity of, or
activity in, the trading market for any of the securities.
Agents, underwriters, dealers and remarketing firms may be
customers of, engage in transactions with, or perform services
for, us, our subsidiaries in the ordinary course of business.
The anticipated date of delivery of securities will be set forth
in the applicable prospectus supplement relating to each offer.
17
VALIDITY
OF SECURITIES
Unless otherwise indicated in the applicable prospectus
supplement, the validity of our debt securities, common stock,
preferred stock, warrants, purchase contracts and units will be
passed upon for us by Davis Polk & Wardwell LLP.
EXPERTS
The consolidated financial statements and managements
assessment of the effectiveness of internal control over
financial reporting (which is included in Managements
Report on Internal Control over Financial Reporting)
incorporated in this prospectus by reference to the Annual
Report on
Form 10-K
for the year ended December 31, 2008 have been so
incorporated in reliance on the report of PricewaterhouseCoopers
LLP, an independent registered public accounting firm, given on
the authority of said firm as experts in auditing and accounting.
ERISA
MATTERS
CIGNA and certain of its affiliates, including Connecticut
General Life Insurance Company and Life Insurance Company of
North America, may each be considered a party in
interest within the meaning of the Employee Retirement
Income Security Act of 1974, as amended (ERISA), or
a disqualified person within the meaning of the
Code, with respect to many employee benefit plans subject to
Title I of ERISA or Section 4975 of the Code or
entities deemed to hold the assets of such Plans (each, a
Plan). Prohibited transactions within the meaning of
ERISA or the Code may arise, for example, if securities are
acquired by a Plan with respect to which CIGNA or any of its
affiliates is a service provider, unless such securities are
acquired pursuant to an exemption for transactions effected on
behalf of such Plan by a qualified professional asset
manager or pursuant to any other available statutory,
class or individual exemption. In addition, certain
governmental, church and
non-U.S. plans
are subject to federal, state, local or
non-U.S. laws
that are substantially similar to Section 406 of ERISA or
Section 4975 of the Code (Similar Laws).
Therefore, each purchaser or holder of the securities or any
interest therein will be deemed to have represented by its
purchase or holding thereof that either (i) it is not and
is not using the assets of any Plan or any plan subject to
Similar Laws or (ii) its purchase and holding of the
securities or any interest therein will not constitute or result
in a nonexempt prohibited transaction under Section 406 of
ERISA or Section 4975 of the Code or in a similar violation
of Similar Laws.
Any Plan or plan subject to Similar Laws proposing to invest in
the securities should consult with its legal counsel. The sale
of the securities offered hereunder to any Plan or plan subject
to Similar Laws is in no respect a representation by CIGNA or
any of its affiliates that such an investment is appropriate for
or meets all relevant legal requirements with respect to
investments by any such Plan or plan subject to Similar Laws
generally or any particular Plan or plan subject to Similar Laws.
18
$600,000,000
CIGNA Corporation
4.500% Senior Notes due
2021
5.875% Senior Notes due
2041
PROSPECTUS SUPPLEMENT
March 2, 2011
Joint Book-Running Managers
BofA Merrill Lynch
Morgan Stanley
Wells Fargo
Securities